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Abstract  
 
The endocannabinoid system plays essential roles in normal physiology and a variety of disease 
states. A component of this system is the type-2 cannabinoid receptor (CB2); a G protein-coupled 
receptor predominantly expressed in peripheral tissues, primarily in the immune system.  Thus, CB2 
is a promising candidate therapeutic target for treating inflammation, diabetes, cancer, pain, and 
other diseases.  However, CB2-selective drug candidates thus far have failed in clinical trials.  A 
contributor to this problem is difficulties in developing CB2
-selective compounds.  As a result, 
novel therapeutic strategies for modulating CB2 are currently under study, with allosteric 
modulation being proposed as a potentially important approach for targeting CB2 receptors.  A 
positive allosteric modulator would potentiate the functional response to an orthosteric agonist, 
allowing affinity modulation and/or efficacy modulation. However, proper spaciotemporal 
regulation of signalling would theoretically remain under physiological control due to the allosteric 
compound being dependent on an endogenous orthosteric ligand.  The compounds C2 and A5 are 
among the first small synthetic CB2 positive allosteric modulators (PAMs) reported. This project 
aimed to characterise the molecular pharmacology of these allosteric modulators together with a 
series of proposed novel allosteric modulators (which comprise analogues of C2 and A5, and novel 
compounds from a in silico virtual screen) at CB2 using G protein dissociation (TRUPATH) and β-
arrestin-2 translocation assays; both real-time bioluminescence resonance energy transfer (BRET) 
assays. Assays were conducted in human embryonic kidney (HEK) cells, where compounds were 
tested alone, and in the presence of the orthosteric agonist CP55,940. Results showed that neither 
C2 or A5 could modulate CP55,940-dependent G protein dissociation or CP55,940-dependent β-
arrestin-2 translocation at CB2, contradicting the published evidence describing these compounds as 
PAMs.  However, C2 was active as an agonist alone. Surprisingly, C2 alone also induced G protein 
dissociation at the CB1 receptor, and increased CP55,940-dependent G protein dissociation through 
CB1, suggesting that this compound is both an agonist and a positive allosteric modulator at CB1 
(i.e., an ago-PAM).  The remaining set of proposed novel allosteric modulators (C2 and A5 
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analogues and “hits” from the in silico virtual screen) did not able appear to modulate CP55,940-
dependent G protein dissociation or CP55,940-dependent β-arrestin-2 translocation at CB2.   The 
findings from this study add to the body of work on allosteric modulators of CB2 and highlight 
discrepancies from published literature, which present C2 and A5 as PAMs. Therefore further 
investigation requires more rigour to address these differences.  
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1.  Introduction 
The endocannabinoid system (ECS) is a lipid signalling system that appeared early in evolution and 
is involved in essential regulatory functions throughout the body (Rodriguez de Fonseca et al., 2005). 
Anandamide (AEA) and 2-arachidonoylglycerol (2-AG), small molecules derived from arachidonic 
acid, are the central endogenous agonists of the ECS, which bind to the G protein-coupled receptors 
(GPCRs), the CB1 and CB2 cannabinoid receptors (Devane et al., 1988; Matsuda et al., 1990; Munro 
et al., 1993; Sugiura et al., 1994).  CB1 and CB2 have seven-transmembrane-spanning domains that 
contain intervening intracellular loops and C-terminal domains (Howlett, 2005).  The activation of 
both CB1 and CB2 leads to the subsequent stimulation of Gi/o heterotrimeric proteins, which are 
coupled to the inhibition of adenylate cyclase (AC).  This corresponds to the inactivation of the 
protein kinase A (PKA) phosphorylation pathway and the stimulation of mitogen-activated protein 
kinase (MAPK).  These intracellular events lead to the regulation of many cellular processes (Di 
Marzo et al., 2004).  Due to the role cannabinoid receptors and their endogenous lipid ligands play in 
regulatory functions in health and disease, there has been an exponential growth of studies exploiting 
the ECS for therapeutic use (Finn et al., 2021; Kanchumarthi et al., 2021; Rodríguez Mesa et al., 
2021; Seillier, 2021; Steardo et al., 2021).  CB1 is among the most densely expressed GPCRs in the 
brain (Glass et al., 1997), where its activation produces pronounced psychotropic effects. These side  
effects have limited the potential development of CB1 agonists and antagonists (Morales et al., 2018).  
In contrast, CB2 is predominantly expressed in peripheral tissues, such as the immune system, where 
it modulates immunological function, cell migration and cytokine release (An et al., 2020).  Thus, 
CB2 is a promising target to be considered in diseases with an inflammatory component such 
as multiple sclerosis, autoimmune diseases, and cancer (Morales et al., 2018), as well as some types 
of chronic pain (Anand et al., 2009).  Among researchers, much is expected of the therapeutic 
opportunities offered by the activation of CB2.   Approaches exist in GPCR drug discovery that may 
offer improved potential for therapeutic benefit. Recently, studies have proposed that ligands can 
differentially activate numerous pathways by stabilising the receptor in different conformations. This 
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concept is referred to as “biased signalling” (discussed below) and represents a new therapeutic 
opportunity to target pathways that elicit desired responses while avoiding pathways that may elicit 
detrimental effects (Urban et al., 2007).  In addition, many GPCRs possess allosteric sites that offer 
potential in drug discovery by offering new paradigms for modulation of receptor function without 
requiring occupancy of the orthosteric site where they compete with endogenous ligands (Keov et al., 
2011).  Allosteric modulators are now being proposed as an important potential avenue for targeting 
CB2, with the possibility of inducing biased signalling. If successful, this will provide major advances 
in the development of novel drugs and research tools for CB2.  
 
1.1. Allosteric Modulators 
 
 
1.1.1. What are Allosteric Modulators? 
 
GPCRs contain allosteric binding sites for endogenous and/or synthetic ligands, discrete from the 
orthosteric binding site (Conn et al., 2009).  Allosteric binding sites vary to include extracellular 
regions, interior regions, the lipid-facing exterior of the transmembrane helix bundle, and intracellular 
regions (Kenakin & Miller, 2010; Wold et al., 2018).  When an allosteric modulator binds to this 
allosteric site, it may induce a conformational change, either dependent or independent of the 
orthosteric ligand. Consequently, it allows the finetuning of the pre-existing actions of the 
endogenous ligands in a time and spatially dependent manner (Ross, 2007).  Allosteric modulators 
therefore exhibit affinity modulation and/or efficacy modulation.  Affinity modulation impacts the 
orthosteric binding pocket such that either the association or dissociation rate (or both) of an 
orthosteric ligand is modified (Schwartz & Holst, 2007).  An allosteric modulator can act as a positive 
allosteric modulator (PAM), potentiating the functional response to an orthosteric agonist, or as a 
negative allosteric modulator (NAM), reducing the functional response to an orthosteric agonist 
(Kenakin & Miller, 2010).  There have been reports of compounds that are agonists, but also display 
allosteric properties, referred to as ago allosteric modulators (ago-PAM).  Such compounds can act 
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as co-agonists, providing additive effects and increasing agonist potency (Schwartz & Holst, 2007).  
In addition, there are neutral allosteric ligands (NALs), which do not modulate the receptor function 
but have the ability to compete with PAMs or NAMs at the allosteric binding site (Schwartz & Holst, 
2006).  Lastly, there are bitopic ligands that bind to both the orthosteric and allosteric sites (Valant et 
al., 2009).  Allosteric ligands may also have an intrinsic agonist profile in the absence of an orthosteric 
ligand, despite binding to the allosteric site (Wold et al., 2018).  
 
1.1.2. Advantages of Allosteric Modulators 
 
Compounds that exert an allosteric action hold a number of theoretical advantages over orthosteric 
ligands as potential therapeutic agents, which have been extensively reviewed (Christopoulos & 
Kenakin, 2002; Conn et al., 2009; Kenakin & Miller, 2010; Wold et al., 2018).  First, allosteric site 
residues are less conserved among receptor subtypes, offering subtype-specific targeting.  Second, 
pure allosteric modulators exert effects only in locations where orthosteric ligands are present – in 
vivo, this allows endogenous ligand tone to determine where allosteric modulators will be active. 
Additionally, having such selectivity may enable allosteric ligands provide synergising effects with 
other co-administered modulators.  Pure allosteric modulators are saturable in their effects, as once 
the allosteric site is completely occupied, further allosteric effect is not observed (ceiling effect).  
This is unlike competitive orthosteric ligands, for which the effects can be theoretically infinite as 
they depend on the concentration of the competing compound, as a high concentration will produce 
a comparably high magnitude of effect.  Therefore, allosteric modulators avoid the risk of 
pharmacodynamic overdose as they can be given in quite high doses if required.  Allosteric 
modulators may also have the advantage of probe dependence, which is the ability of allosteric 
modulators to affect different agonists in completely different ways (Bartuzi et al., 2019).  For 
example, a certain modulator can increase a receptor’s response when a specific ligand is bound, 
or have no effect at all when bound by a different ligand.  This could be particularly useful in the 
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cannabinoid system as there is more than one endogenous ligand.  Lastly, allosteric modulators 
might allow control of the receptor signalling without desensitisation, tolerance and dependence 
(Gado et al., 2019).  These advantages all contribute to the possibility of having precise 
pharmacological modulation.  While this drug discovery approach is still new, there are already 
approved allosteric modulators on the market such as Cinacalcet - PAM of calcium sensing receptor 
(CaS) for the treatment of hyperparathyroidism, Maraviroc – NAM of chemokine receptor 5 
(CCR5) for prevention of cellular entry of HIV1, Plerixafor – allosteric agonist of CXC chemokine 
receptor 7 (CXCR7) that encourages stem cell production for the treatment of lymphoma and 
multiple myeloma (Block et al., 2004; Lounsbury, 2020; Perry, 2010).  These exciting 
advancements provide clear proof of the clinical utility of allosteric modulators of GPCR.  Research 
also suggests that allosteric modulators can induce biased signalling.  PAMs may selectively 
activate or enhance specific signalling pathways (e.g. G proteins over β-arrestins) due to the 
stabilisation of specific receptor conformations.  Whereas, NAMs may selectively block certain 
signalling pathways over others (Gao & Jacobson, 2013).  Finally, it is important to take into 
consideration that often, allosteric modulators have some amount of inherent agonism or inverse 
agonism in the absence of an orthosteric ligand.  How allosteric agonism differs from orthosteric 
agonism in terms of functional response is still not well explored; however, given the different 
binding modes, it is feasible that the conformation of the receptors would be distinct and therefore 
potentially open to different signalling interactions.  It is hoped that this feature can be exploited 
pharmacologically to silence undesirable effects and potentiate desired ones induced by the same 
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1.2. Current Understanding of the CB2 Receptor 
 
 
1.2.1. CB2 as a therapeutic target? 
 
Cannabinoid CB2 receptors belong to the class A (rhodopsin family) of G protein-coupled receptors 
and were first discovered by Munro et al. (1993).  CB2 is a therapeutic target to find novel 
cannabinoid-related drugs for CNS and other inflammatory diseases.  This is on the basis that CB2 
has restricted expression in comparison to CB1, which is expressed in most brain regions and in 
many neuronal cell types.  Fewer side effects are expected when drugs are targeting receptors with 
restricted expression than when drugs are targeting receptors widely expressed in the CNS (Navarro 
et al., 2016). Furthermore, the key location in which CB2 is expressed, allows the preservation of 
neuronal integrity (presence of CB2 in the blood-brain barrier, BBB, is critical for the maintenance 
of the CNS integrity) (Chung et al., 2016; Vendel & de Lange, 2014) and survival, making it a 
promising therapeutic target.  In addition to this, the CB2 receptor is a promising candidate for 
diseases with a neuroinflammatory component due to its involvement in endocannabinoid 
regulation of microglial activation (Navarro et al., 2016).  CB2 also has major therapeutic potential 
outside the brain; this is on the basis that several behavioural and neurochemical studies have 
shown CB2
 activation to be involved in the modulation of inflammatory nociception in a variety of 
pain states.  For example, CB2 is a promising candidate in treating inflammatory pain as CB2 can 
control cytokine release, overall playing a role in immune system regulation (Anthony et al., 2020).  
Currently, the treatment of patients with inflammatory pain is difficult and challenging.  Animal 
models have shown CB2 to be involved in inhibiting acute and chronic inflammatory pain, while 
preclinical studies have shown CB2 not to produce central nervous system effects (psychoactive 
effects).  Therefore, CB2 shows promise for the treatment of inflammatory pain conditions without 
the possibility of eliciting negative cannabinoid effects (psychoactive effects) (Malan Jr et al., 
2003). 
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1.2.2. CB2 Structure, Critical Residues and Ligand Entry  
 
CB2 shares a common architecture with other GPCRs, consisting of seven transmembrane helices 
(TMH1-7) linked by alternating intracellular and extracellular loops. The extracellular receptor 
surface and transmembrane bundle are critical for ligand binding, whereas the intracellular receptor 
surface is known to be involved in G protein recognition and activation (Wess, 1997).  CB2 has a high 
degree of homology and shares 44% amino acid identity with CB1, with an additional 68% shared 
identity within their transmembrane domains (Munro et al., 1993).  Unsurprisingly, most ligands do 
not discriminate between receptor subtypes, making it difficult to delineate CB1- vs CB2-selective 
compounds (Tao et al., 1999).  To address these issues with selectivity, mutational and ligand binding 
studies, functional mapping, and computer modelling have been used to probe the nature of ligand 
interaction with the cannabinoid receptors.  Li et al. (2019) reported on the crystal structure of human 
CB2  in complex with a rationally designed antagonist, AM10257, in efforts to elucidate the size and 
identify critical residues of the CB2 pharmacophore.  Findings showed that the CB2 antagonist-
binding pocket is distinct and relatively smaller than the CB1 antagonist-binding pocket. The 
CB2 antagonist-binding pocket and the CB1 agonist-binding pocket share similarities in size and 
ligand-interacting residues.  In regards to ligand binding to human CB2, mutagenesis studies have 
revealed a crucial role for Ser112 for the recognition of several cannabinoid ligands (Tao et al., 1999). 
The same study showed that, unlike the CB1 receptor in which residue Lys192 plays a vital role in 
the binding of most cannabinoid ligands, the homologous conserved residue Lys109 in the CB2 TM3 
domain does not appear to be a key residue.  A later study by Hua et al. (2020) went on to report on 
the agonist (AM12033) bound crystal structure of CB2 using single-particle cryoelectronic 
microscopy (cryo-EM). In the CB2/AM12033 complex, AM12033 adopts an L-shape conformation 
in the orthosteric binding pocket.  The study also revealed that the interactions between AM12033 
and CB2 are mainly hydrophobic and aromatic.  Another recent study by Pandey et al. (2020) used 
computational approaches to characterise allosteric sites within the agonist bound (CP55,940) 
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complex of CB2, using known negative CB2 allosteric modulators (NAMs); dihydro-gambogic acid 
(DHGA) and trans-beta-caryophyllene (TBC).  Five potential allosteric bindings pockets were found 
in the CB2/CP55,940 complex. Results also showed that these NAMs affected the CB2-CP55,940 
complex by adjusting the positioning of toggle switch residues and promoting interaction between 
Phe1173.36 and Trp2586.48.  It is hoped that greater subtype selectivity could be achieved by targeting 
these allosteric binding sites.  Overall, these studies explain that there is some overlap between the 
CB1 and CB2 binding sites, but, importantly, differences that may be exploitable in the discovery of 
selective ligands.   
 
Ligand entry to cannabinoid receptors may be via the lipid bilayer, which can be attributed to the fact 
that endocannabinoids and all known CB2 ligands are highly lipophilic (Hurst et al., 2010).  This 
assumption has been supported by isothiocyanate covalent labelling studies, which has suggested the 
classical cannabinoid, AM841 enter the cannabinoid CB2 receptor via the lipid bilayer (Pei et al., 
2008).  To elucidate the steps of this pathway, Hurst et al. (2010) reported on unbiased molecular 
dynamic simulations of the interaction of 2-AG with CB2 via the lipid bilayer.  Results showed 2-AG 
to first partition out of bulk lipid at the TMH6/7 interface and then enter the CB2 receptor binding 
pocket via a portal that forms between TMH6 and TMH7.  The findings mentioned above demonstrate 
that a lipid pathway for ligand binding is necessary for CB2. 
 
1.2.3. Ligands of CB2 and Associated Effects 
 
A full consideration of the range of CB2 ligands that have been synthesised is beyond the scope of 
this review.  However, it is important to mention that at least three non-psychotropic CB2 agonists 
exist: HU-308, AM-1241 and JWH-133, all holding promise in multiple health issues such as 
inflammatory conditions, chronic pain, neuropathic pain, malignant lymphomas, and hypertension 
(Hanuš et al., 1999; Huffman et al., 1999; Ibrahim et al., 2005).  Additionally, these agonists show 
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high selectivity for CB2  (KD: 0.33) versus CB1 (KD: 0.10)  (Soethoudt et al., 2017).  Rajesh et al. 
(2008) investigated the ability of CB2 agonists, JWH‐133 and HU‐308, to modulate inflammatory 
stimuli involved in the development and progression of atherosclerosis and restenosis.  Results 
showed both agonists to dose‐dependently attenuate TNF‐α‐induced smooth muscle proliferation and 
migration in human coronary artery smooth muscle cells (HCASMCs), providing a novel approach 
to treating such pathologies.  However, irrespective of this hope, due to the predominance of CB2 in 
immune cells, it is necessary to take certain precautions as immune dysfunction can result following 
activation.  This is illustrated through a study that showed HU-308 to aggravate inflammation in a 
mouse model of DNFB-induced cutaneous contact in hypersensitivity via a cannabinoid CB2 -
dependent mechanism (Ueda et al., 2005), contradicting the evidence which shows CB2 to be anti-
inflammatory.  Although subtle differences are often seen between ligands, further understanding of 
these factors and the molecular mechanisms that influence these contrasting outcomes is necessary.  
 
 
1.3.  Biased Agonism at the CB2 Receptor 
 
 
A potential reason for the lack of translation across studies may be that CB2 agonists show biased 
agonism (also known as functional selectivity).  Here, a difference in agonist efficacy across species 
and types of pathological conditions can be observed (Atwood et al., 2012; Soethoudt et al., 2017).  
Biased agonism is the ability of a ligand to engage in different signal transduction pathways over 
others by stabilising different active conformational states of the receptor (for example, G protein 
signalling or β-arrestin-dependent signalling) in order to obtain a specific receptor response (Urban 
et al., 2007) (Figure 1).  This differential activation can cause differences in intrinsic activity and/or 
potency between signal transduction pathways.  This concept holds therapeutic promise as it raises 
the possibility of designing novel compounds that are optimized to have an improved efficacy towards 
specific effectors (Wootten et al., 2018).  Biased signalling is hoped to yield more targeted drugs as 
it offers the theoretical possibility of designing drugs/ligands that activate therapeutically relevant 
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pathways while avoiding those that lead to unwanted or adverse side effects.  However, in terms of 
CB2, it is important to acknowledge that it is currently unknown what the various signalling pathways 
cause as a system-level endpoint.  Nevertheless, biased agonism has impacted GPCR drug discovery 
significantly, such as through the μ opioid receptor.  The beneficial analgesic effects of the μ opioid 
receptor are mediated through G protein pathways. In contrast, adverse effects such as constipation, 
respiratory depression and tolerance, are mediated through β-arrestin-dependent pathways (Conibear 
& Kelly, 2019).  Hence, novel G protein-biased μ opioid receptor agonists are thought to provide a 
therapeutic advantage over conventional μ opioid receptor agonists as they are predicted to have a 
better adverse effect profile.  Overall, a structural understanding of the compound-receptor 
interactions that drive these distinct cellular pathways are still required. Additionally, even where 
there is rationale for favouring G protein signalling or β-arrestin dependent signalling, it is currently 
unknown the extent to which a biased ligand must favour one signalling pathway over another to 
produce a therapeutic effect (Luttrell & Lefkowitz, 2002).  
 
At many GPCRs, signalling events mediated by G proteins and β-arrestins have been shown to have 
distinct biochemical and physiological consequences (Smith et al., 2018).  CB2 is well-characterised 
in G protein signalling.  G proteins are comprised of an alpha (Gα), beta (Gβ), and a gamma (Gγ) 
subunit, which are associated with the plasma membrane.  In their inactive heterotrimeric state, the 
Gα subunit is bound to guanosine diphosphate (GDP) to form a stable complex with the Gβγ dimer 
(Hamm, 1998).  Following the binding of a ligand, a conformational change occurs in the GPCR, 
allowing the G proteins to interact with the receptor (De Lean et al., 1980).  This catalyses the 
exchange in the Gα-bound guanosine diphosphate (GDP) for guanosine triphosphate (GTP).  This 
exchange causes the Gα subunit to dissociate from the Gβγ subunit, and initiate G protein signalling – 
for CB2; the Gα subtype is Gαi/o, which acts to inhibit adenylyl cyclase (AC) activity.  This corresponds 
to a reduction in PKA activity or leads to the stimulation of the MAPK pathway (Di Marzo et al., 
2004).  Consequently leading to a variety of intracellular events that regulate several cellular 
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processes.  The signal is terminated via the intrinsic GTPase activity of the Gα subunit, which 
hydrolyses GTP to GDP.  This transition allows the reassociation of the Gα and Gβγ subunits to reform 
the inactive heterotrimer (Duc et al., 2017). 
 
Figure 1: Biased agonism at the cannabinoid receptor 2. Different ligands will selectivity engage 
in specific cellular pathways over others by stabilising different active conformational states of the 
receptor. In this diagram, agonist 1 is biased toward the activation of G protein signalling over β-
arrestin-2 signalling, while agonist 2 is biased towards β-arrestin-2 signalling.  Solid lines indicate 
a direct pathway, while dotted lines indicate an indirect pathway. 
 
CB2 is less characterised as a β-arrestin-coupled receptor.  β-arrestins are adapter proteins that form 
complexes with GPCRs following the binding of an agonist and plays a central role in 
desensitisation and internalisation (Luttrell & Lefkowitz, 2002).  This process involves G protein 
receptor kinases (GRKs) phosphorylating the receptor following agonist binding.  Phosphorylation 
promotes the high-affinity binding of arrestin to the receptor.  Arrestins bind to domains of the 
receptor, which interact with G proteins, preventing the receptor from further activation.  This 
eventually removes the receptor from the plasma membrane by internalisation (Gurevich & 
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Gurevich, 2019).  However, arrestins are also thought to mediate some downstream signalling, as 
they can act as scaffolding molecules for non-G protein-mediated signalling pathways, such as for 
MAPKs (Jean-Charles et al., 2017). 
 
Soethoudt et al. (2017) profiled a number of cannabinoid receptor ligands in multiple signal 
transduction pathways (GTPγS, cAMP, β-arrestin) at both mouse and human CB2, with the aim of 
investigating functional selectivity.  Results showed high variability in the potencies and efficacies 
of the ligands tested across different signalling pathways.  For example, in the GTPγS assay 
conducted at human CB2, HU308 acted as a potent full agonist while WIN55212-2 only acted as a 
partial agonist.  In the GTPγS assay conducted at mouse CB2, HU308 and JWH133 behaved as full 
agonists, while HU910 was only partially active.  Whereas in the cAMP assay, HU210, CP55940, 
and WIN55212-2 exhibited the highest potency.  All ligands modulated β-arrestin at hCB2; 
however, CP55940 was the most potent ligand in this assay.  Conclusions on bias cannot be 
conducted by comparing potencies and efficacies as these are assay and system dependent.  
Therefore, in order to quantify this display of ligand bias, Soethoudt et al. (2017) conducted an 
operational analysis based on van der Westhuizen et al. (2014).  The operational analysis is based 
on a model by Black and Leff (Black & Leff, 1983), which calculates the signal transduction 
strength on a given signalling pathway while taking into account different factors such as the 
maximal effect of the system, the maximum efficacy of the agonist, agonist concentrations, affinity 
of the ligand and the transducer slope (Soethoudt et al., 2017).  This analysis method allows 
prediction of whether a ligand’s activity in one pathway will predict its activity in another 
(compared to a reference ligand); if activity cannot be translated into a different signalling pathway, 
there is evidence for bias.  Results from the operational analysis revealed that the CB2 ligands 
showed statistically significant bias towards different signalling pathways over others, with 
differing efficacies across species.  For example, on the operational analysis conducted on human 
CB2, WIN55212-2 was biased towards GIRK compared to cAMP signalling, whereas  JWH133 
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showed preference towards β-arrestin compared to GIRK signalling. On the operational analysis 
conducted on mouse CB2, HU308 and JWH133 were significantly biased towards G-protein 
signalling over cAMP and β-arrestin signalling, emphasising the species-specific differences. 
 
Our understanding of biased G protein signalling or β-arrestin mediated-signalling is still limited 
for CB2, with no strongly β-arrestin-biased CB2 agonists having been found so far. Furthermore, 
functional selectivity in the cannabinoid system is ambiguous as certain signalling responses have 
not been correlated with a distinct desirable or undesirable outcome. Hence, the potential role of 
arrestin-biased or G protein-biased ligands therapeutically is therefore not clear. However, with the 
knowledge that CB2-selective ligands show functional selectivity, there is a renewed opportunity to 
explore this area of research. 
 
 
1.4.  Allosteric Modulators of CB2  
 
 
Allosteric modulators of CB2 represents a promising therapeutic strategy for the treatment of 
multiple disorders.  To date, very few allosteric modulators for CB2 have been reported.  The first 
allosteric modulator reported at CB2  is pepcan-12, belonging to a family of endogenous peptide 
endocannabinoids (Petrucci et al., 2017).  Petrucci et al. (2017) investigated the effects of this 
endogenous ligand on the modulation of CB2 -mediated signalling by measuring G protein 
activation, cAMP production and β-arrestin-2 recruitment.  Results showed that pepcan-12 did not 
trigger or inhibit any of the CB2 -mediated signalling pathways measured in the absence of the 
orthosteric ligands.  However, in the presence of CP55,940 or 2-AG, it induced a significant 
potentiation of cAMP inhibition and GTPγS binding, but did not influence β-arrestin-2 recruitment. 
These results suggest that pepcan-12 might act as a PAM for CB2, showing signal bias for 
regulating G protein activity over β-arrestin-2 recruitment.  The occurrence of this endogenous CB2 
PAM is intriguing, as it implies that part of the normal, native ECS may be controlled by a 
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compound that has not yet been extensively studied.   Further replication research is needed to 
further this area of research. 
 
Gado et al. (2019) recently presented evidence of the first synthetic PAM modulator of CB2, a 
compound termed “C2”.  Evidence of C2 acting as a PAM was obtained by carrying out CP55,940 
receptor binding assays and G protein activation assays (measured by [35S]GTPγS incorporation) in 
CHO cell membranes overexpressing CB1 and CB2.  Results showed C2 to strongly increase the 
binding of CP55,940 to CB2 at 1nM to 1µM concentrations.  The GTPγS assays showed 100 nM C2 
to enhance the ability of CP55,940, 2-AG but not AEA to stimulate G protein activation.  Results 
also showed that in the absence of the orthosteric ligand, C2 did not produce any stimulation or 
inhibition of GTPγS binding, indicating that it does not possess the ability to affect CB2 
functionality alone.  In CB1-expressing cells, C2 was able to increase the binding of CP55,940 up to 
a concentration of 1µM.  However, C2 was not able to potentiate the agonism of CP55,940 in the 
GTPγS assay.  C2 was also tested in cold allodynia assays to investigate its effect on neuropathic 
pain, with results showing C2 to dose-dependently reverse the lowering of the threshold to cold 
stimuli, representative of anti-nociceptive activity. The combined results from this study indicate 
that C2 is a CB2 PAM both in vitro and in vivo.  However, there are important considerations that 
need to be addressed in regards to this study, which is that their concentration-response curves are 
often poorly defined, and the potency of C2 has not been well established.  For example, the authors 
interpreted that C2 strongly increased the binding of CP55,940 to CB2, suggesting that it may be a 
PAM (Figure 2).  However, the data this was based on is challenging as there was no increase in 
binding induced by C2 at 10µM at CB2, raising concerns about this conclusion's rigour.  This may 
be due to the possibility of off-target effects, and hence may need further investigation.  
Additionally, no vehicle controls are described for the CP55,940 binding and GTPγS functional 
assays, these are essential in determining the validity of the results.  Nevertheless, this study 
provides basis for further studies exploring allosterism at CB2. 








Figure 2. Effects of C2 (at 1 nM to 10 μM) on CP55940 binding to CB2. Results show that C2 
increased the binding of CP55,940 at very low concentrations suggesting that C2 may be a CB2 
PAM. Asterisks indicate mean values significantly different from zero (*P < 0.05; **P < 0.01; 
****P < 0.0001). Figure reproduced from Gado et al. (2019). 
 
A follow-up study was conducted by Gado et al. (2021), where the C2 compound was further  
modified into several different analogues in efforts to better understand the structural requirements 
for the binding to the CB2 allosteric site (Figure 3). 
Figure 3: Structure of compound C2 and of the new derivatives A1 and A5. Figure reproduced 
from Gado et al. (2019); Gado et al. (2021).  
 
The analogues were characterised in vitro through radioligand binding experiments and functional 
assays (cAMP, β-arrestin-2, GTPγS) in CHO cells overexpressing hCB2.  Results from radioligand 
binding experiments showed that out of the C2 analogues, compounds A1 and A5 (see Figure 3) 
enhanced the binding of CP55,940 to CB2.  Subsequent experiments further went on to test the 
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ability of A1 and A5 to increase CP55,940 binding to hCB2 in a concentration-dependent (1 nM - 
10 μM) manner.  A1 and A5 induced approximately 20% and 40% increases in the binding of 
[3H]CP55,940, respectively, between 1 nM and 10 μM (Figure 4).  These results however are very 
complex to interpret, as the lowest concentrations showed the largest difference from the vehicle 
point, thus 1-100nM produced a significant increase in binding (shown as negative displacement), 
while, as for C2, 10µM did not significantly alter binding (and the minimum concentration assayed 
also produced the maximum effect).  The effect at low concentrations could suggest that the drugs 
have very high affinity for the receptor, and that even lower concentrations are required to see a full 
concentration response curve, although this would not explain why the effect is lost at higher 
concentrations. In the [35S]GTPγS assay, in the absence of the orthosteric ligand, A5 (1 nM - 
10 μM) did not produce significant stimulation or inhibition at CB2  (Figure 5).  However, A1 
produced a slight decrease in activation at the highest concentrations tested (1 and 10 μM), although 







Figure 4: Effects of compounds A1, A5, A7 (at 
1 nM - 10 μM) on [3H]CP55,940 binding to 
hCB2. Results show A1 and A5 to induce 
approximately 20% and 40% increases in the 
binding of [3H]CP55,940, respectively, between 
1 nM and 10 μM. Whereas, A7 only affected the 
binding of [3H]CP55,940 to a negligible extent. 
Asterisks indicate mean values significantly 
different from basal for each corresponding 
colour; ∗p < 0.05, ∗∗p < 0.01 relative to basal 
control. Figure reproduced from Gado et al. 
(2021). 
Figure 5: CB2 [35S]GTPγS binding assays 
performed in the presence of A1 or A5 in the 
absence of the orthosteric ligand. Results show 
A1 to produce a slight decrease in [35S]GTPγS 
binding at the highest concentrations tested, 1 
and 10 μM. On the contrary, A5 did not produce 
significant stimulation or inhibition of 
[35S]GTPγS binding to CB2. Asterisks indicate 
mean values significantly different from basal 
for each corresponding colour; ∗p < 0.05, 
∗∗p < 0.01 relative to basal control. Figure 
reproduced from Gado et al. (2021). 
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GTPγS binding was repeated under the conditions above but in the presence of increasing 
concentrations of CP55,940 (1 nM - 10 μM) (Figure 6), where a small but significant increase 









Figure 6: CB2 [35S]GTPγS binding assays performed with CP55,940 and compound A1 or A5. 
A1 and A5 did not significantly alter the potency of CP55,940 for [35S]GTPγS binding to CB2 at 1-
10 μM of allosteric ligand. A1 and A5 were able to cause a small, but significant increase in Emax at 
100nM of the allosteric ligand. Asterisks and carets in graphs indicate mean values significantly 
different from CP55,940 + DMSO control; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 1 nM compound 
relative to CP55,940 + DMSO; ^p < 0.05, ^^p < 0.01 100 nM compound relative to CP55,940 + 
DMSO Figure reproduced from Gado et al. (2021). 
 
Finally, the authors investigated cAMP signalling and β-arrestin-2 recruitment for A1, A5 and the 
parent compound C2 (called EC21a in this paper).  The results showed that C2 and both 
analogues A1 and A5 increased CP55,940-dependent signalling in both assays, consistent with 
PAM activity.  C2 and A5 had nanomolar potency, while A1 produced a linear response in the 
concentration range tested.  A consistent trend for all compounds was that their potency was greater 
in the inhibition of cAMP assay than the β-arrestin 2 recruitment assay.  
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1.5. Further Research Required for Allosterism at the CB2 receptor 
 
Although the results obtained from the Gado papers are promising, further studies must be carried 
out to investigate the allosteric effects of the PAMs mentioned above.  It is essential to carry out 
additional functional assays in vitro, to understand the mechanism of action of these compounds.  It 
has been proposed that allosteric modulators may be more readily characterised in dynamic 
screening assays as opposed to accumulation assays (Burford et al., 2011).  If a PAM response has 
transient activity, then, in an accumulation assay such as cAMP, a poor signal to background ratio 
would lead to low sensitivity (Denis et al., 2012). It is also necessary to consider differences 
between G protein binding (which occurs proximal to the receptor), and the signalling endpoints 
that are measured several degrees downstream from ligand binding and receptor activation, as these 
may be altered by signal amplification (Buchwald, 2019). Different receptor expression levels can 
affect how a compound behaves; for example, a partial agonist may behave as a full agonist due to a 
high receptor expression level (Finlay et al., 2017; Finlay et al., 2020).  Further investigations into 
the CB2 PAMs could use an assay with less receptor reserve to avoid distortion of receptor 
signalling due to amplification.  GPCR ligands can show bias towards distinct intracellular G 
protein or arrestin pathways; therefore, it is essential to further investigate the functional selectivity 
of the reported PAMs.  Recently, a BRET2-based biosensor to measure the activation of G-protein 
has been reported (Olsen et al., 2020), utilising luminescently labelled heterotrimer subunits to 
detect G protein dissociation, which is used for the direct measurement of ligand-receptor-
transducer coupling.  We can exploit such assays for the mentioned CB2 allosteric modulators to 
determine functional selectivity.  Lastly, it’s important to consider that the proposed ligands may 
have non-specific effects at other non-cannabinoid receptors.  Therefore, further investigations are 
necessary to elucidate these non-specific effects and whether they may reduce the potential 
usefulness of CB2 mediated effects. 
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1.6. Research Aims 
 
This project aims to characterise the molecular pharmacology of the previously described allosteric 
modulators of CB2 (C2 and A5) and a set of proposed novel allosteric modulators at CB2 in in vitro 
functional assays.  These novel compounds have been rationally developed by collaborator, Andrea 
Vernall from the Department of Chemistry and School of Pharmacy at the University of Otago.  Some 
are novel analogues of the Gado compounds, modified to be more hydrophilic, UOSD029, 
UOSD030, and UOSD031.  The rationale behind designing these novel analogues was to attach polar 
substituents off the N-benzyl to reduce classical orthosteric binding while retaining some allosteric 
behaviour.  The other novel compounds have entirely novel chemistry and have emerged from an in 
silico virtual screening approach; these include IL-405507, IL-405512, IL-405514 and IL-405517.  
The extant antipsychotic drug haloperidol and the commercially available compound Z2 (Enamine) 
were also hits in the in silico screen, and so were purchased and included in this study.  In addition 
to a detailed characterisation of these putative allosteric compounds at CB2, receptor subtype 
selectivity (a theoretical advantage of allosteric modulators generally) will also be interrogated by 
screening compounds at CB1. 
 
Characterisation of these compounds will be done through: 
• G Protein Dissociation: Evaluated using a bioluminescence resonance energy transfer 
assay. This assay utilises BRET2-tagged G protein sub-units to measure the activation of 
G protein, a platform dubbed TRUPATH (Olsen et al., 2020).   
• β Arrestin Translocation: β-arrestin-2 translocation will be investigated using a real-time 
BRET assay. This assay utilises a BRET1 based approach (Donthamsetti et al., 2015) to 
investigate the recruitment of β-arrestin to the cell surface.  
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Assays will be conducted in human embryonic kidney (HEK) cells expressing receptors of interest. 
Compounds will be tested alone, and in the presence of the orthosteric agonist CP55,940. These in 
vitro assays will seek to reproduce the findings of Gado et al. (2019) and Gado et al. (2021) to 
further describe the activity of C2 and A5 at CB2, and also to provide a comparative basis for 
functional characterization of the novel compounds reported in this thesis.  
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Figure 7: Series of compounds tested. C2 and A5 are published allosteric modulators of CB2. The 
UOSD compounds are analogues of C2 and A5, synthesised in the Department of Chemistry.  The 
remaining compounds emerged from an in silico virtual screen conducted by the Department of 
Chemistry: IL-4 compounds are novel compounds that were synthesised, as opposed to Z2 
(Enamine) and Haloperidol, which were commercially available.  
  
 Page | 30 
2.  Materials and Methods 
2.1. Drugs 
 
C2 (N-[5-Bromo-1,2-dihydro-1-(4′-fluorobenzyl)-4-methyl-2-ox- opyridin- 
3yl]cycloheptanecarboxamide), A5 (N-(5-bromo-1-(2-chlorobenzyl)-4-methyl-2-oxo-1,2 
dihydropyridin-3yl)-cycloheptane-carboxamide), and Z2 ( (naphthalen-2-yloxy)-1-(4-(2- 
phenylacetyl)piperazin-1-yl)ethan-1) were provided by Andrea Vernall (University of Otago). 
Analogues of C2 and A5 (UOSD029, UOSD030, UOSD031) and compounds from the virtual 
screens (IL 405507, IL-405512, IL-405514, IL-405517) were also provided by Andrea Vernall 
(University of Otago).  Haloperidol (4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-
fluorophenyl)butan-1-one) was purchased from Cayman Chemical Co.  CP55,940 ((-)-cis-3-[2 
Hydroxy-4- (1,1-dimethyl heptyl)phenyl]-trans-4-hydroxypropyl) cyclohexanol [Side Chain-2, 3, 4 
3H(N)] was purchased from Cayman Chemical Co.  All drugs were prepared in DMSO at 31.6 mM 
and stored at -80 C (as single use aliquots).  For a detailed list of materials see the Appendix. 
 
2.2. Cell Lines 
 
All live cell experiments were conducted using commercially-sourced human embryonic kidney 
293 (HEK293) cells.  Two HEK 293 cell lines were utilised for this project:  
• HEK 293 Wild Type (wt.): Wild-type, immortalised HEK cell line 
• HEK 293/ 3HA-hCB1: This cell line has been stably transfected to express CB1.  This cell 
line which has previously been described in Cawston et al. (2013),  has antibiotic resistance 
to zeocin. Therefore, 250 μg/μL zeocin (Thermo Fisher Scientific) was added when 
passaging. 
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2.2.1. Cell Culture and Maintenance 
 
HEK293 cells were maintained in high glucose, phenol red-containing Dulbecco's Modified Eagle 
Medium (DMEM, ThermoFisher Scientific) supplemented with 10% foetal bovine serum (FBS) 
(Moregate Biotech).  Cells were maintained in either a 25 cm2  (T25) or 75 cm2 (T75) vented-cap 
flask and kept in a humidified incubator at 37 °C with 5% CO2.  Cells were passaged (subcultured) 
when the confluency of the cells reached 80-90%.  Passaging was conducted by aspirating and 
discarding the media, followed by washing in phosphate-buffered saline (PBS).  Cells were then 
incubated with 1 ml or 2 ml (T25, T75 respectively) 0.05% Trypsin-EDTA (ThermoFisher 
Scientific) at 37° C for approximately 5 minutes.  Medium was added to dilute and inactivate the 
trypsin, followed by thorough trituration to break cell clusters and achieve a single cell suspension.  
The desired fraction of cells were kept in the flask, with the excess either discarded or retained for 
counting and plating for assays.  Maintenance flask culture volumes were 5 mL (T25) or 10 mL 
(T75).  
 
2.2.2. Seeding and Transfection 
 
Cells retained after passaging were counted using trypan blue (ThermoFisher Scientific) 
haemocytometry to determine the concentration of cells/mL.  Cells were seeded in 10 cm diameter 
cell culture dishes (Corning®) at either 2 million cells (for transfection after 48 h), or 3.5 million 
cells (for transfection after 24 h), diluted to 8 mL in complete medium and cultured at 37 °C in 5% 
CO2.  When cells were 50-60% confluent, cells underwent a 50% medium change (to optimise cell 
growth and transfection), and transfection mixture was added.  Transfections for the assays used 
PEImax diluted in OptiMEM, and a total DNA amount of 4 µg/10 cm dish. The ratio of DNA: 
PEImax was 1:9 and the total transfection mixture volume (per dish) was 1 mL.  Cells were 
incubated for 24 hours with the transfection mix before plating.  
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2.2.3. Plating 
 
24 hours after transfection, cells in 10 cm dishes were passaged and counted as described above 
(2.2.1), and then diluted in complete medium to 600,000 cells/mL.  Wells of 96-well, white 
CulturPlates (PerkinElmer) and several wells of a clear-bottom 96-well plate (Corning®) were pre-
treated for 30 minutes in a cell culture incubator with 50 µg/mL high molecular weight poly-d-
lysine (PDL, Sigma), and then washed with PBS prior to plating.  Cells were plated at 60,000 
cells/well in a volume of 100 μL/well.  Assays were conducted in the 96-well CulturPlates at least 
16 hours later (while cell health and confluency were evaluated prior to assaying in the clear bottom 
plates). 
 
2.3. G Protein Dissociation 
 
Cells were passaged and seeded in 10 cm dishes, and transfected with PEImax as described above. 
Standard transfection mixture comprised the following DNA species in a 1:1:1:1 ratio of receptor 
and each TRUPATH component (1 µg each; 4 µg total DNA amount): 
 
• TRUPATH – Gαi3-Rluc8 pcDNA5/FRT/T0 
• TRUPATH – Gβ3 pcDNA3.1 
• TRUPATH – Gγ9-GFP2 pcDNA3.1 
• pplss (preprolactin signal sequence)-3HA-hCB2 63R pEF4a 
• Empty pcDNA3.1 (to keep total DNA amount consistent between transfection conditions) 
- Used in CB1 assays (for which receptor was stably expressed). 
 
DNA was diluted in OptiMEM (ThermoFisher Scientific) for a final volume of 500 µL.  In a 
separate tube, 36 µL of 1 mg/ml PEImax was diluted in OptiMEM for a final volume of 500 µL.  
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The DNA and PEImax OptiMEM mixtures were combined and incubated at room temperature for 
20 minutes.  During the incubation, the culture medium in the dish was 50% replaced.  Transfection 
mixtures were then added dropwise to dishes and returned to the incubator overnight.  The next day, 
transfected cells were lifted, and replated in PDL-coated, white 96-well CulturPlates and 
subsequently left to incubate for at least 16 hours, as described previously. 
 
On assay day, wells were washed with 70 µL PBS and then serum-starved in 70 µL Assay Medium 
(phenol red-free DMEM supplemented with 1 mg/mL BSA and 25 mM HEPES pH 7.4) for 30 
minutes.  After serum starve was complete, 10 μL of coelenterazine-400a was added to cells (for a 
final concentration of ~5 µM), and a 5 minute read was performed in a BMG Labtech LUMIstar® 
luminometer using BRET2 filters (410-80 nm and 515-30 nm, detected simultaneously) in order to 
establish a “pre-drug” baseline (this is referred to as a “pre-read”).  Drugs were prepared at 10x 
final concentration (in Assay Medium) and 20 µL was added per well, for a total stimulation 
volume of 100 μL/well.  Vehicle load was standardised for a final exposure of 0.1% DMSO and 
0.21% ethanol when the drugs were dispensed onto the cells.  As soon as drugs were dispensed, the 
plate was returned to the LUMIstar and read for a further 20 minutes.  BRET ratios were calculated 
in BMG Labtech software (MARS) as GFP2 (515 nm) emissions divided by RLuc8 (410 nm) 
emissions.  In GraphPad Prism (v9.1.2), data for each run were visualised as a kinetic trace, then 
baseline-corrected using the “vehicle only” condition.  Area-under-the-curve (AUC) analysis was 
then performed in Prism for the kinetic trace in the presence of drug (i.e., excluding the pre-read), 
and data were represented in concentration-response format as ΔBRET.sec.  Where appropriate 
responses were observed, a 3 parameter concentration-response curve (“log[agonist] vs response (3 
parameters)”) was fitted to the data for interpolation of potency (pEC50) and efficacy parameters.  
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2.4. β-Arrestin Translocation 
 
Cells were passaged and seeded as described above. Transfections for β-arrestin Translocation 
assay follow the PEImax method (described above). 
 
Plasmids transfected per 10 cm dish were as follows: 
• Mem-linker-Citrine-SH3 pcDNA3.1, 500 ng/µL 
• pplss-3HA-hCB2 63R pEF4a Cl.1, 500 ng/µL 
• RLuc8-hβ-Arrestin-2-Sp1 pcDNA3.1, 25 ng/µL 
• Empty pcDNA3.1, 350 ng/µL 
 
The plasmids described above were transfected similarly to that described in the G protein 
dissociation assay.  However, DNA was diluted in an intermediate step in MilliQ, prior to being 
diluted to the final desired quantity in OptiMEM.  Total DNA amount was 4 µg per dish, and the 
same 1:9 DNA:PEImax ratio previously described was retained. 
 
Assays were performed similarly to the TRUPATH assay described above, except that 
coelenterazine H was used in place of coelenterazine 400a, and luminescence signals were detected 
in the LUMIstar using BRET1 (535-30 and 475-30) filters instead of BRET2 filters.  Data were 
collected as BRET ratios in MARS; mCitrine (535 nm) emission divided by Rluc8 (460 nm) 
emission.  In analysis, the pre-mean pre-read BRET ratio signal was subtracted from all kinetic 
data.  The drug response traces were then baseline-corrected and area-under-the-curve (AUC) 
analysis was performed as described above (GraphPad Prism v9.1.2).  The AUC values were used 
to generate concentration-response curves, which were fit with 3-parameter curves (where 
appropriate) in GraphPad Prism. 
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2.5. Data Analysis 
 
GraphPad Prism v9.1.2 was used for all data analysis.  Concentration-response curves were 
modelled by fitting a three-parameter (“log[agonist] vs response (3 parameters)”), nonlinear 
regression curve, using GraphPad Prism.  EC50 and spans were extrapolated from the curves to 
define potency and Emax values.  The graphs presented are representative figures of one 
independent sample. A repeated measures one-way ANOVA (assuming sphericity) with a Holm-
Šídák post hoc test was done to explore differences between treatment groups, with p values 




 Page | 36 
3.  Results 
3.1. G Protein Dissociation Assay 
 
The G protein Dissociation assay entails a series of BRET2-based biosensors to measure the 
activation of G protein pathways, and was recently published as a platform called TRUPATH 
(Olsen et al., 2020).  The initial steps that initiate G protein signalling cascades include the activated 
GPCR interacting with the Gα subunit, leading to an exchange of the Gα- bound guanosine 
diphosphate (GDP) for guanosine triphosphate (GTP).  This exchange causes the Gα subunit to 
dissociate from the Gβγ subunit and initiate G protein signalling.  In this assay, the Gα subunit is 
fused to the BRET donor, a modified form of Renilla Luciferase (Rluc8), which catalyses the 
conversion of coelenterazine-400a to coelenteramide, subsequently emitting light at 410nm.  The 
BRET acceptor GFP2 is fused to the Gβγ subunit.  When the receptor is in its inactive state, the 
donor and acceptor are within close proximity; therefore, the donor (Rluc8) can non-radioactively 
transfer energy to the acceptor (GFP2), exciting it.  This leads to the subsequent emission of light 
from the acceptor protein at 515nm.  However, following G protein dissociation, the donor and 
acceptor move away from each other, leading to a decrease in resonance energy transfer.  The 
decrease in the resonance energy transfer between the luminescently labelled heterotrimer subunits 
therefore detects dissociation and can be used as a proxy for direct measurements of ligand-
receptor-transducer coupling (Figure 8).   
 
Compounds were evaluated for G protein dissociation in HEK293 cells transiently transfected with 
CB2, or in cells stably expressing CB1.  The compounds were tested at the receptor alone, and in the 
presence of an approximate EC50 concentration of CP55,940, an agonist of the cannabinoid 
receptors in order to detect allosteric effects (positive or negative).  The emitted wavelengths were 
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simultaneously detected in real-time by a LUMIstar®  (BMG Labtech) luminometer, where BRET 
ratios were collected as a ratio of GFP2 emissions to RLuc8 emission (515/410nm). 
 
 
Figure 8: Graphical Representation of the G Protein Dissociation Assay. Bioluminescence 
Resonance Energy Transfer (BRET2) between Gα-RLuc8 donor proteins and fusion Gγ-GFP2 
acceptor proteins differentiate between the inactive and active Gαβγ heterotrimers.  (A) When the 
receptor is inactive, the Gα-RLuc8 donor and Gβγ-GFP2 acceptor are in close proximity; hence 
there is a high resonance energy transfer between the labelled heterotrimer subunits.  (B) Upon 
activation of the receptor, the Gα subunit dissociates from the Gαβγ heterotrimer.  This decreases 
the resonance energy transfer between the labelled heterotrimer subunits, allowing for direct 

















 Page | 38 
3.1.1. Characterisation of C2, A5, Z2, and Haloperidol at CB2 
Figure 9:  G Protein Dissociation produced by novel cannabinoid ligand, C2, in the absence or 
presence of CP55,940 at CB2. Representative raw BRET traces of BRET2 ratio showing G Protein 
dissociation levels reached by maximal drug concentrations over 25 minutes, alone (A), and in the 
presence of CP55,940 (C). Representative concentration response curve of  C2 (alone) (B), and in 
the presence of EC50 CP55,940 (D). Data is expressed as the mean difference in BRET Ratio 
(515/410 nm) ± SEM from of each respective condition of a representative experiment (n=3 
technical replicates) (B, D).  1µM CP55, 940 (-6M) was included as an internal control in each 
assay.  
 
Initial studies characterised C2, A5, Z2 and Haloperidol as they were available immediately, while 
the remaining compounds were being synthesised.  Figure 9 shows the novel cannabinoid 
compound C2 in G Protein dissociation, alone and in the presence of EC50 CP55,940 at CB2.  
Results from the kinetic traces indicate that C2 alone (Figure 9A) increased G protein dissociation 
at CB2, as seen by the decrease in BRET2 ratio at the highest concentrations.  However, there was 
no detectable effect observed in the kinetic trace for C2 in the presence of  EC50 CP55,940 (Figure 
9C).  Area under the curve analysis was conducted on the time course data allowing concentration-
response curves to be produced.  Similar to the observations made from the kinetic data, the 
concentration response curves indicate that C2 alone (Figure 9B) increased G protein dissociation at 
CB2, although this effect was not as efficacious as the positive control CP55, 940 (1µM).  No 
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additional effect was observed in the presence of CP55,940 beyond the dissociation produced by 
CP55,940 alone (Figure 9D).  The response produced at 10µM of C2 was extrapolated from the 
concentration response curves, following which a repeated measures one-way ANOVA with a 
Holm-Šídák post hoc test was done to explore differences between treatment group and vehicle. 
Results showed that C2 produced a statistically significant decrease of -62.86 ± 13.33 ΔBRET.sec 
(p<0.05) from vehicle, confirming the observations made from the kinetic traces and concentration 
response curves.  Overall, C2 was able to increase G protein dissociation, suggesting that this 
compound was able to act as an agonist at CB2.  However, C2 did not significantly alter the 
dissociation induced by EC50 CP55,940 (Figure 11B), suggestive that C2 is not a positive allosteric 
modulator.  This directly contradicts the published literature (Gado et al., 2019), which suggests 
that C2 is a positive allosteric modulator. 
 
Figure 10 shows G protein dissociation produced by the remaining published novel CB2 allosteric 
ligand A5, and the commercially available compounds; Z2 and Haloperidol (identified to be 
possible allosteric modulators from an in vitro screen).  These compounds had no detectable effect 
observed in the kinetics traces either alone (Figure 10 A-C), or in the presence of an approximate 
EC50 concentration of CP55,940 (Figure 10 G-I).  Concentration-response curves were produced 
for each compound alone (Figure 10 D-F) and in combination with EC50 CP55,940 (Figure 10 J-L), 
and statistical testing was done comparing the compound (10µM) to the vehicle.  Results show that 
none of these compounds altered receptor activity, and in the presence of CP55,940, they were 
inactive except at concentrations above 10µM where a small inhibition was observed.  However, 
statistical analysis did not identify any significant modulation of CP55,940-mediated G protein 
dissociation for any of the novel compounds, indicating that they are not acting as allosteric 
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Figure 10:  G Protein Dissociation produced by novel cannabinoid ligands in the absence or 
presence of CP55,940 at CB2 . Representative raw BRET traces for the published novel CB2 
allosteric ligand (A5), and commercial compounds (Z2 and Haloperidol) of BRET2 ratio showing 
G protein dissociation levels reached by maximal drug concentrations over 25 minutes, alone (A, B, 
C), and in the presence of CP55,940 (G, H, I). Representative concentration response curve of 
ligands alone (D, E, F), and in the presence of CP55,940 (J, K, L) in G protein dissociation. Data is 
expressed as the mean difference in BRET Ratio (515/410 nm) ± SEM from of each respective 
condition of a representative experiment (n=3 technical replicates) (D, E, F, J, K, L). 1µM CP55, 








 Page | 41 
Figure 11:  Area under the curve (AUC) analysis of G Protein dissociation in response to novel 
cannabinoid ligands in the presence or absence of CP55,940 at CB2. G Protein Dissociation 
mediated by 10µM of novel allosteric ligands either alone (A) or in the presence of EC50 CP55,940 
(B). Data are presented as the AUC of the normalised BRET ratio (515nm/410nm) ± SEM. Each 
value represents mean AUC from a single experiment, for n=3 independent biological replicates 
(individual values are also shown as data points). *indicates significance relative to vehicle (p < 
0.05). 
 
3.1.2. Published Compounds C2 and A5 at CB1: Testing for Selectivity 
 
Cannabinoid ligands share affinity for both canonical cannabinoid receptor subtypes.  However, an 
advantage that allosteric modulators hold is that they have the theoretical benefit of greater subtype 
selectivity over orthosteric ligands.  This attribute still requires empirical confirmation; therefore, in 
order to test for receptor subtype selectivity for CB2, compounds C2 and A5 were tested in HEK293 
stably expressing CB1.  Both compounds were tested at the CB1 receptor alone, and in the presence 
of EC50 CP55,940.  Upon observing the kinetic traces for C2 alone, G protein dissociation at CB1 
increased as shown by a decrease in BRET2 ratio at higher concentrations (Figure 12A).  This 
observation can be translated to the AUC analysis conducted on the time course for C2 alone 
(Figure 12B), in which a concentration-dependent response can be observed.  This suggests that C2 
is an agonist at CB1, where it is at least as efficacious as the positive control CP55,940.  On the 
contrary, it is difficult to see a response for C2 in combination with CP55,940 from the kinetic 
traces alone, as the C2 allosteric agonism effect is dominating the CP55,940 effect (Figure 12C). 
Therefore it is difficult to differentiate the PAM effect from the allosteric agonism effect.  However, 
when analysing the AUC, it is evident that an allosteric effect is present as the C2 concentration 
response curve Emax ends with slightly greater efficacy than the CP(-6) point, leading to an obvious 
decrease in ΔBRET.sec (Figure 12D).  The kinetic traces for A5 at CB1 suggest that this compound 
may be an inverse agonist due to high concentrations of the drug inducing reduced G protein 
dissociation in comparison to the vehicle point (Figure 12E).  The concentration response curve 
produced from the AUC analysis confirms this interpretation as an increased ΔBRET.sec can be 
observed at higher concentrations of A5 (Figure 12F).  There was no detectable effect observed with 
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A5 in the presence of EC50 CP55,940 from both the kinetic trace and the concentration response 
curve (Figure 12G and 12H), suggesting that any potential inverse agonism is insufficient to 























Figure 12: G Protein Dissociation produced by novel cannabinoid ligands in the absence or 
presence of CP55,940 at CB1. Representative raw BRET traces for the two published novel CB2 
allosteric ligands of BRET2 ratio showing G protein dissociation levels reached by maximal drug 
concentrations over 25 minutes, alone (A, E), and in the presence of EC50 CP55,940 (C, G). 
Representative concentration response curve of ligands alone (B, F), and in the presence of 
CP55,940 (D, H) in G protein dissociation. Data is expressed as the mean difference in BRET Ratio 
(515/410 nm) ± SEM from of each respective condition of a representative experiment (n=3 
technical replicates) (B, D, F, H). 1µM CP55, 940 (-6M) was included as an internal control in 
each assay.  
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Figure 13: Area under the curve (AUC) analysis of G Protein dissociation in response to novel 
cannabinoid ligands in the presence or absence of CP55,940 at CB1. G Protein Dissociation 
mediated by 10µM of the published ligands either alone (A) or in the presence of EC50 CP55,940 
(B). Data are presented as the AUC of the normalised BRET ratio (515nm/410nm) ± SEM. Each 
value represents mean AUC from a single experiment, for n=3 independent biological replicates 
(individual values are also shown as data points). *indicates significance relative to vehicle (p < 
0.05). 
 
Statistical testing was done comparing response produced by the compound (10µM) to the vehicle 
in order to explore differences between treatment group and vehicle (repeated measures one-way 
ANOVA with a Holm-Šídák post hoc test).  Results from the statistical analysis confirmed the 
observations made from the kinetic traces and concentration response curves as C2 produced a 
statistically significant decrease of -75.64 ± 12.95 ΔBRET.sec (p<0.05) from vehicle, suggesting 
that this compound was able to act as an agonist at CB1 (Figure 13A).  A5 induced a significant 
increase of 34.19 ± 2.22 ΔBRET.sec (p<0.05) from vehicle, suggesting that this compound may be 
an inverse at CB1 (Figure 13A).  Results show that C2 in the presence of EC50 CP55,940, induced a 
twofold increase  in G protein dissociation, from vehicle (-40.60 ± 2.78 ΔBRET.sec) to CP55,940 
conditions (-80.60 ± 2.77 ΔBRET.sec) (p<0.05) (Figure 13B).  No significant change was observed 
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3.1.3. Analogues of C2 and A5: UOSD029, UOSD030, UOSD031 
 
Figure 14: G Protein Dissociation produced by analogues of C2 and A5: UOSD029, UOSD030, 
UOSD031 in the absence or presence of CP55,940 at CB2. Representative raw BRET traces of 
BRET2 ratio showing G protein dissociation levels reached by maximal drug concentrations over 
25 minutes, alone (A, B, C), and in the presence of CP55,940 (G, H, I). Representative 
concentration-response curves from AUC of ligands alone (D, E, F), and in the presence of 
CP55,940 (J, K, L) in G protein dissociation. Data is expressed as the mean difference in BRET 
Ratio (515/410 nm) ± SEM from of each respective condition of a representative experiment (n=3 
technical replicates) (D, E, F, J, K, L). 1µM CP55, 940 (-6M) was included as an internal control 
in each assay.  
 
Analogues of the novel cannabinoid compounds C2 and A5; UOSD029, UOSD030, and UOSD031, 
were tested in G protein dissociation at increasing concentrations at CB2, at the receptor alone and 
in the presence of EC50 CP55,940.  No evident changes were observed from the kinetic data for the 
analogues at the receptor alone (Figure 14 A-C) or in the presence of EC50 CP55,940 (Figure 14 G-
I). AUC analysis was conducted on the time course data allowing concentration-response curves to 
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be produced. UOSD029 and UOSD030 did not produce a concentration response curve (Figure 14D 
and 14E) at CB2.  However, the concentration-response curve produced for UOSD031 suggested 
that there was a small increase in ΔBRET.sec at high concentrations (Figure 14F).  There was no 
detectable change observed for G protein dissociation for any of the analogues in the presence of EC50 
CP55,940 (Figure 14 J-L).  However, it is important to note that at the highest concentration of 
UOSD031 (31.6µM), this compound may be competing with CP55,940 as there is a slight increase 
in ΔBRET.sec (Figure 14L).  Statistical testing was done comparing compound (10µM) to vehicle 
(repeated measures one-way ANOVA with a Holm-Šídák post hoc, p<0.05) to explore differences. 
The analysis confirms that UOSD031 at CB2 produced a statistically significant increase of 34.83 ± 
2.80 ΔBRET.sec (p<0.05), consistent with inverse agonist activity at CB2  (Figure 15A).  No 
significant changes were identified for the remaining analogues at the receptor alone. UOSD029 in the 
presence of EC50 CP55,940 showed a statistically significant decrease (-101.00 ± 8.103 ΔBRET.sec) 
from the CP55,940 condition alone (-68.72 ± 8.103 ΔBRET.sec) (p<0.05) (Figure 15B).  This 
indicated that UOSD029 may be a PAM at CB2, as it was able to increase G protein dissociation 
levels above CP55,940 conditions, although a high degree of variability was present.  Neither of the 
remaining analogues in the presence of EC50 CP55,940 were significantly different from the CP55,940 
alone conditions (Figure 15). 
 
Figure 15: Area under the curve (AUC) analysis of G Protein dissociation in response to 
analogues of C2 and A5 in the presence or absence of CP55,940 at CB2. G Protein Dissociation 
mediated by 10µM of analogue either alone (A) or in the presence of EC50 CP55,940 (B). Data are 
presented as the AUC of the normalised BRET ratio (515nm/410nm) ± SEM. Each value represents 
mean AUC from a single experiment, for n=4 independent biological replicates (individual values 
are also shown as data points). *indicates significance relative to vehicle (p < 0.05).  
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3.1.4. IL-4 Compounds from Virtual Screen 
 
A virtual screen performed by collaborators in the Department of Chemistry suggested a number of 
putative allosteric modulators of CB2, which were synthesised and subsequently investigated for 
activity in the TRUPATH G protein dissociation paradigm.  From the raw kinetic traces for assays 
in which the IL-4 compounds were used alone, no apparent changes from vehicle can be observed, 
as the drug concentration traces lies directly on top of the vehicle trace (blue) (Figure 16A, C, E, 
G).  The same applies for the kinetic data where the IL-4 compounds were added with EC50 
CP55,940 (Figure 16B, D, F, H).  AUC analysis was conducted on the kinetic data allowing 
concentration-response curves to be produced.  No activity is observed at the receptor alone for all 
IL-4 compounds.  In the presence of CP55,940, there is also no concentration response observed.  
Statistical testing was conducted on the IL-4 compounds, comparing compound (10µM) to vehicle 
(repeated measures one-way ANOVA with a Holm-Šídák post hoc test, p<0.05).  Surprisingly, 
statistically significant increases in ΔBRET.sec from vehicle were present for all IL-4 compounds at 
the CB2 receptor alone; (Figure 17; IL-405507: 11.23 ± 1.31 ΔBRET.sec, IL-405512: 17.44 ± 6.20 
ΔBRET.sec, IL-405514: 17.18 ± 2.95 ΔBRET.sec and IL-405517: 17.98 ± 3.50 ΔBRET.sec). 
However, looking back to the AUC analysis (Figure 16I), the statistically significant differences seen 
may not be an accurate reflection of these drugs’ activities.  This is because a baseline shift is 
visible between the vehicle point and the lowest drug concentration in the series, implying that this 
shift may be an assay artefact.  In the presence of EC50 CP55,940, all IL-4 compounds (IL-45507 (-
110.70 ± 3.38 ΔBRET.sec), IL-45512 (-108.70 ± 3.34 ΔBRET.sec), IL-45514 (-104.9± 2.60 
ΔBRET.sec), Il-405517 (-95.96 ± 5.34 ΔBRET.sec) caused a statistically significant decrease in 
ΔBRET.sec from vehicle (-84.61 ± 6.68 ΔBRET.sec) (p<0.05) (Figure 17B). 
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Figure 16: G Protein Dissociation produced by compounds from a virtual screen in the absence 
or presence of CP55,940 at CB2. Representative raw traces of BRET2 ratio showing G protein 
dissociation levels reached by maximal drug concentrations over 25 minutes, alone (A, C, E, G), 
and in the presence of EC50 CP55,940 (B, D, F, H). Representative concentration response curve 
of ligands alone (I), and in the presence of CP55,940 (J) in G protein dissociation. Data is 
expressed as the mean difference in BRET Ratio (515/410 nm) ± SEM from of each condition of a 
representative experiment (n=3 technical replicates) (I, J). 1µM CP55, 940 (-6M) was included as 
an internal control in each assay.  
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Figure 17: Area under the curve (AUC) analysis of G Protein dissociation in response to 
compounds from a virtual screen in the presence or absence of EC50 CP55,940 at CB2 . G 
Protein Dissociation mediated by compounds alone (10µM) (A), or in the presence of CP55,940 
(B). Data are presented as the AUC of the normalised BRET ratio (515nm/410nm) ± SEM. Each 
value represents mean AUC from a single experiment, for n=5 independent biological replicates 
(individual values are also shown as data points). *indicates significance relative to vehicle (p < 
0.05). 
 
3.1.5. Different Experimental Design: IL-4 Compounds + UOSD029 
 
A variation to the original experimental design was employed to further investigate and clarify 
whether the IL-4 compounds showed positive allosteric activity.  One of the C2/A5 analogues, 
UOSD029, was also included in this part of the study, as it showed PAM activity in the original 
experimental design.  Instead of performing concentration-response curves for the putative 
allosteric compounds, here, CP55,940 concentration-response curves were performed in the 
presence of vehicle, or three concentrations of each IL-4 compound and UOSD029 (10 nM, 100 
nM, 1μM).  The rationale for this altered approach was to provide a more sensitive way of 
investigating possible subtle allosteric compound effects that are agonist-dependent and may have 
been missed in previous assay designs.  This is based on the knowledge that allosteric modulators 
have the theoretical ability to be silent in the absence of agonist, and their effects vary across the 
range of concentrations at which the agonist is active.  Figure 18 shows representative CP55,940 
concentration-response curves at various compound concentrations (10 nM, 100 nM, 1 μM), where 
no difference can be observed between CP55,940 alone or in combinations with any concentrations 
of the IL-4 compounds and UOSD029.  Statistical testing was conducted comparing the Emax (span, 
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%) and the potency (EC50) (repeated measures one-way ANOVAs, p<0.05).  There was no 
significant difference between the Emax or EC50 values between CP55,940 alone or in combinations 
with any concentrations of the IL-4 compounds or UOSD029 (Table 1) (p < 0.05). 
 
 
Figure 18: G Protein Dissociation produced by virtual screen compounds and an analogue of C2 
and A5 (UOSD029) at various concentrations (10 nM, 100 nM, and 1 μM) in the presence of  
CP55,940 at CB2. Representative CP55,940 concentration response curve at various 
concentrations of putative allosteric ligands in G protein dissociation. Data is expressed as the 
mean difference in BRET Ratio (515/410 nm) ± SEM from of each respective condition of a 
representative experiment (n=3 technical replicates). 1µM CP55, 940 (-6M) was included as an 
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Table 1: Potencies and efficacies of CP55,940 as modified by ligands investigated at three 
different concentrations (10 nM, 100 nM, and 1 μM ) for G Protein Dissociation.*  
 


















































































































*Potency/pEC50 and Emax values obtained using three-parameter non-linear regression on GraphPad Prism 
v9.2.1. Emax values were obtained from the regression curve spans. Number of individual experiments conducted 
denoted by n, each experiment was conducted in technical triplicates. Data expressed as mean ± SEM. *indicates 
significance relative to vehicle (p < 0.05). 
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3.2. β-Arrestin Translocation Assay 
 
The β-Arrestin Translocation assay described here was first used by Donthamsetti et al. (2015) 
(Figure 19).  This assay utilises a BRET1-based approach. β-arrestin is fused to the BRET donor 
modified Renilla Luciferase (Rluc8), which catalyses the conversion of coelenterazine-h to 
coelenteramide, subsequently emitting light at 475nm.  The BRET acceptor mCitrine is fused to the 
membrane-targeting fragment of neuromodulin (GAP43).  Thus, the assay detects β-arrestin 
translocation to the cell membrane following receptor activation.  When the donor and acceptor are 
in close proximity, the donor (Rluc8) resonates energy to the acceptor (mCitrine), thereby exciting 
it.  This leads to the subsequent emission of light from the acceptor protein at 535 nm.  The emitted 
wavelengths are then simultaneously detected in real-time by the LUMIstar® plate reader, allowing 
the measurement of β-arrestin-2 translocation in response to ligands binding to the receptor of 




Figure 19: Graphical representation of the β-arrestin Translocation Assay. (A) When the receptor 
is inactive, the β- arrestin fused RLuc8 is not within close proximity to Citrine; there is no 
resonance energy transfer between the donor and acceptor; hence light is emitted at 475nm. (B) 
Upon activation of the receptor, β-arrestin translocates nearer to the cell membrane, and 
resonance occurs between RLuc8 and Citrine, leading to an increased emission of 535nm. Figure 
drawn in Biorender. 
 Page | 52 
3.2.1. Characterisation of C2, A5, Z2 and Haloperidol at CB2 
 
Figure 20: β-arrestin-2 translocation in response to the novel allosteric compound C2, in the 
absence or presence of EC50 CP55,940 at CB2. Representative raw traces of BRET1 ratio showing 
β-arrestin-2 translocation levels reached by maximal drug concentrations over 25 minutes, alone 
(A), and in the presence of EC50 CP55,940 (C). Representative concentration response curve of C2 
(alone) (B), and in the presence of EC50 CP55,940 (D) in β-arrestin-2 translocation. Data is 
expressed as the mean difference in BRET Ratio (535/474 nm) ± SEM from of each respective 
condition of a representative experiment (n=3 technical replicates) (B, D). 1µM CP55, 940 (-6M) 
was included as an internal control in each assay.  
 
The study of these compounds was extended by performing β-arrestin translocation assays.  β-
arrestins are known to play a central role in receptor desensitisation and internalisation, and are 
therefore a consequence of receptor activation that may not be captured in the G protein 
dissociation assays described above.  Figure 20 shows β-arrestin translocation of the published 
allosteric modulator, C2, alone and in the presence of EC50 CP55,940 in HEK293 cells transiently 
transfected with CB2.  Representative kinetic traces show that there is an increase in BRET1 ratio 
for higher concentrations of C2 at the receptor, suggestive of agonist activity (Figure 20A). 
Although, important to note that C2 was not as efficacious as the CP55,940 (1 µM) control.  A 
small effect can be seen from the kinetic data for C2 in the presence of CP55,940, as the kinetic 
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traces for all the C2 concentrations do not appear to be on top of each other (Figure 20C).  Kinetic 
data were analysed by taking the area under the curve allowing concentration-response curves to be 
produced.  A concentration dependent increase in β-arrestin-2 translocation can be seen for C2 at 
CB2, confirming the effects seen from the kinetic profile (Figure 20B).  However, there is no clear 
additional effect of C2 on CP55,940  β-arrestin-2 recruitment (Figure 20D).  
 
Figure 21: β-arrestin-2 translocation in response to novel allosteric compounds in the presence 
or absence of EC50 CP55,940 at CB2. Representative raw BRET traces for the published novel 
CB2 allosteric ligand (A5) and commercial compounds (Z2 and Haloperidol) of BRET1 ratio 
showing β-arrestin-2 translocation levels reached by maximal drug concentrations over 25 minutes, 
alone (A, B, C) and in the presence of EC50 CP55,940 (G, H, I). Representative concentration 
response curve of compound (alone) (D, E, F), and in the presence of EC50 CP55,940 (J, K, L) in 
β-arrestin-2 translocation. Data is expressed as the mean difference in BRET Ratio (535/474 nm) ± 
SEM from each respective condition of a representative experiment (n=3 technical replicates) (D, 
E, F, J, K, L). 1µM CP55, 940 (-6M) was included as an internal control in each assay.  
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β-arrestin translocation was investigated for the remaining published allosteric modulators, A5, and 
the commercially available compounds; Z2 and Haloperidol (Figure 21).  All three compounds 
show no activity at CB2, as observed through both the kinetic and concentration response curves 
obtained from AUC analysis.  Similar to what was observed in the G protein dissociation assay, in 
the presence of CP55,940, none of the compounds affected β-arrestin translocation. 
 
Figure 22:  Area under the curve (AUC) analysis of β-arrestin-2 translocation in response to 
novel cannabinoid ligands (10µM) in the presence or absence of EC50 CP55,940 at CB2. A) β-
arrestin-2 translocation mediated by cannabinoid ligands alone (10µM), or (B) in the presence of 
EC50 CP55,940. Data is presented at the AUC of the normalised BRET ratio (535nm/475nm) ± 
SEM. Each value represents mean AUC from a single experiment for n=4 independent biological 
replicates (individual values are also shown as data points). *indicates significance relative to 
vehicle (p < 0.05). 
 
Figure 22 shows an AUC analysis of changes in β-arrestin-2 recruitment for C2, A5, Z2 and 
Haloperidol (10 μM) in comparison to vehicle.  Statistical testing was applied (repeated measures 
one-way ANOVA with a Holm-Šídák post hoc test)  to explore differences between treatment 
groups and vehicle.  C2 alone significantly increased β-arrestin translocation by 27.55 ± 1.398 
ΔBRET.sec, which is statistically increased from vehicle (p<0.05), indicating that this compound 
may be an agonist in this pathway at CB2.  However, A5, Z2 and Haloperidol at CB2 did not show a 
statistically significant difference from vehicle, and similarly to the G protein dissociation assay, 
C2, A5, Z2 and Haloperidol did not significantly modulate CP55,940-dependent β-arrestin-2 
recruitment activity. 
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Figure 23: β-arrestin-2 translocation in response to virtual screen compounds at a single 
concentration (31.6mM) in the presence or absence of EC50 CP55,940 at CB2. Representative 
raw BRET traces for four putative CB2 allosteric modulators from a virtual screen of BRET1 ratio 
showing β-arrestin-2 translocation levels reached by maximal drug concentrations over 25 minutes, 
alone and in the presence of EC50 CP55,940 (A-D). Data is expressed as the mean difference in 
BRET Ratio (515/410 nm) ± SEM from of each respective condition of a representative experiment 
(n=3 technical replicates). 1µM CP55, 940 (-6M) was included as an internal control in each 
assay.  
 
IL-4 compounds from the virtual screen were tested in the β-arrestin-2 translocation assay at a 
single concentration (31.6µM) in the absence or presence of an approximate EC50 CP55,940 (31.6 
nM) at CB2 (Figure 23).  From the kinetic traces alone, there is no effect at the receptor alone as the 
vehicle trace (blue) lies on top of the ligand trace (red).  On the contrary, it can be observed from 
the kinetic traces that all the IL-4 compounds slightly inhibit the increase in β-arrestin recruitment 
produced by CP55,940 conditions, as the green trace (ligand + CP55,940 condition) consistently 
lies below the yellow trace (CP55,940 only condition).  
 Page | 56 
 
Figure 24:  Area under the curve (AUC) analysis of β-arrestin-2 translocation in response to 
virtual screen compounds in the presence or absence of EC50 CP55,940 at CB2. Area under the 
curve (AUC) analysis of β-arrestin-2 translocation in response to novel allosteric ligands alone (E) 
or in the presence of EC50 CP55,940 (F). Data is presented as the AUC of the normalised BRET 
ratio (535nm/475nm) ± SEM. Each value represents mean AUC from a single experiment, for n=2 
independent biological replicates (individual values are also shown as data points). Due to n<3, 
statistics was not performed. 
 
AUC analysis of changes in β-arrestin-2 recruitment was conducted, however as n<3,  statistical 
testing was not applied (Figure 24).  It’s important to note that there was an assay artefact limiting 
the conclusions that can be drawn from this data.  As seen in Figure 24, out of the biological 
replicates conducted (n=2),  independent assays gave highly divergent results for some compounds. 
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4. Discussion 
Compounds that target CB2 have been proposed to have significant therapeutic potential in a wide 
variety of human diseases, especially in conditions with an inflammatory component such 
as multiple sclerosis, cancer, pain, and autoimmune diseases.  Although CB2 agonists show activity 
in a range of preclinical models, they have translated poorly in clinical trials.  This may be due to 
the lack of selectivity of the ligand, as CB2 selective agonists still generally have an affinity for 
CB1.  As a result of this, allosteric modulation has been proposed to further the investigation into 
CB2 ligands. When an allosteric modulator binds to the allosteric site, it may theoretically allow the 
finetuning of the pre-existing actions of the endogenous ligands in a time- and spatially-dependent 
manner allowing affinity modulation and/or efficacy modulation (van der Westhuizen et al., 2015).  
Additionally, compounds that exert allosteric action hold several theoretical advantages over 
orthosteric ligands as they may offer improved subtype-specific targeting (selectivity), probe 
dependence, and reduced tolerance (Christopoulos & Kenakin, 2002; Conn et al., 2009; Kenakin & 
Miller, 2010; Wold et al., 2018).  Gado et al. (2019) recently presented in vitro evidence of the first 
synthetic PAM modulator of CB2; a compound termed “C2”.  C2  also showed anti-nociceptive 
activity in vivo in an experimental mouse model of neuropathic pain, indicating that this compound 
has activity both in vitro and in vivo.  A follow-up study was conducted by the same group  (Gado 
et al. 2021), where the C2 compound was further modified into several different analogues, 
presenting evidence for another synthetic PAM modulator of CB2, a compound termed “A5”.  
 
This project aimed to characterise the molecular pharmacology of these allosteric modulators (C2 
and A5) and a set of proposed novel allosteric modulators (C2 and A5 analogues, and novel 
compounds from a in silico virtual screen) at CB2 in in vitro functional assays – G protein 
dissociation, and β-arrestin-2 translocation assays.  This section will highlight the findings of the 
study comparatively in the context of the previous literature.  In addition, limitations and further 
directions will be discussed. 
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4.1. G Protein Dissociation 
4.1.1. Published Compounds at CB2 : C2 and A5  
 
This project aimed to use an assay with minimal receptor reserve to avoid distortion of receptor 
signalling that may result from signal amplification.  Hence, compounds were tested by examining 
the initial steps following receptor activation, the activation of a G protein.  Here, a BRET2-based 
biosensor was used to measure G protein dissociation as a direct measurement of ligand-receptor-
transducer coupling.  Compounds were tested in the presence of an approximate EC50 
concentration of CP55,940 to detect allosteric effects with maximum sensitivity (either positive or 
negative).  Compounds were also tested in the absence of CP55,940 to determine if they could 
affect CB2  functionality on their own, as allosteric compounds have the possibility of affecting the 
receptor in the absence of an orthosteric ligand (Wold et al., 2018).  The kinetic data and 
concentration-response curves showed that, in the absence of the orthosteric ligand, C2 significantly 
increased G protein dissociation at CB2 (Figures 9A, 9B, 11A), suggesting that this compound is an 
agonist at CB2.  C2 was not able to modulate G protein dissociation as induced by EC50 CP55,940 
to a significant level in any condition tested in this project; hence no PAM activity was observed.  
Together, these observations suggest that C2 may be best categorised as an allosteric agonist, as it 
was able to mediate receptor activation alone (Schwartz & Holst, 2007).  However, since the C2 
and CP55,940 effects aren’t additive, it should be confirmed that C2 is not acting orthosterically. 
Radioligand binding studies would demonstrate if C2 reacts competitively with CP55,940 for the 
orthosteric binding site, which would help elucidate if it is an “allosteric agonist” or an “agonist”. 
The findings from our current study directly contradict what was previously published by Gado et 
al. (2019), which presented evidence for C2 to act as a PAM.  For example, C2 was able to enhance 
CP55,940-mediated [35S]GTPγS accumulation through CB2 significantly, and strongly increase the 
binding of [3H]CP55,940 at CB2 (1nM to 1µM), suggestive of PAM activity.  However, as 
discussed earlier  (Chapter 1.4), the binding data is quite complex to interpret,  as the lowest 
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concentrations showed the largest difference from the vehicle point, thus 1-100nM produced a 
significant increase in binding (shown as negative displacement), while 10µM did not significantly 
alter binding.  Despite 1nM producing the largest effect, the authors did not attempt lower 
concentrations in order to establish the concentration dependence of this effect, and it is not clear 
that they have controlled for vehicle.  This reduces confidence in the published binding data overall, 
and underscores the need to reproduce the finding.  Given the differences between the published 
literature and the current study, it may be possible that the Gado paper was perhaps misinterpreting 
this evidence of allosteric agonism as allosteric modulation.  Thus the binding assays should be 
repeated to enable confidence that the effect is an allosteric interaction. 
 
The C2 compound was further modified into several different analogues in a follow-up study by 
Gado et al. (2021), where an additional compound, termed “A5”,  showed PAM activity.  Results 
from this project showed that A5 did not produce an effect at CB2.  However, at high 
concentrations, in the presence of the orthosteric ligand CP55,940, it did appear to cause a slight 
upward shift of the curve, but this was not significantly different to the effect produced by 
CP55,940 alone (Figure 10J).  Thus, the finding that A5 was inactive at CB2 agrees with the 
findings from Gado et al. (2021), which showed that A5 did not produce significant stimulation or 
inhibition of [35S]GTPγS binding in the absence of an orthosteric ligand.  However, in contrast with 
the Gado et al. (2021) GTPγS data, in the current study, A5 was not able to induce significant 
modulation of G protein dissociation induced by an EC50 concentration of CP55,940 (Figure 11B) 
(p<0.05). 
 
4.1.2. Exploring Selectivity for published compounds at CB2 : C2 and A5 
 
Many cannabinoid ligands share an affinity for both canonical cannabinoid receptor subtypes due to  
sharing 44% amino acid identity between subtypes (Munro et al., 1993) and containing similar 
binding pockets (Tao et al., 1999).  However, allosteric modulators offer theoretical advantages 
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over orthosteric ligands as they should offer greater subtype selectivity (Christopoulos & Kenakin, 
2002).  This selectivity for a receptor subtype can be via interactions with novel binding sites that 
show greater sequence divergence (Lazareno et al., 2004).  For the purpose of this project, we 
would want these novel allosteric modulators to show cooperativity for the CB2 subtype at the 
exclusion of CB1.  Gado et al. (2019) showed C2 to increase the binding of [
3H]CP55,940 at CB1, 
but showed no functional activity.  Therefore, to further test this, compounds C2 and A5 were tested 
in HEK293 cells stably expressing CB1, where both compounds were tested at the CB1 receptor 
alone and in the presence of EC50 CP55,940.  Results showed that C2 significantly increased G 
protein dissociation  (p<0.05) from vehicle, suggesting that this compound was able to activate the 
receptor, acting as an agonist at CB1 (Figure 12B).  Here, C2 was as efficacious as the positive 
control CP55,940 (1µM). C2 in the presence of EC50 CP55,940 resulted in a twofold increase in G 
protein dissociation from the response produced by CP55,940 (Figure 12D).  An allosteric effect 
was clearly present as the C2 concentration response curve Emax ended with slightly greater 
efficacy than the CP55,940 (1µM) positive control point (Figure 12D).  This directly contradicts the 
findings from Gado et al. (2019), which suggested that C2 was not functionally active at CB1.  
Although no binding studies were conducted in the current study, the results from the functional 
data suggest that C2 acted both as an agonist at CB1 (having intrinsic efficacy of its own) and as a 
positive modulator of the orthosteric ligand, CP55,940 (enhancing its effect).  Gado et al. (2019) 
showed that C2 displayed anti-nociceptive activity in vivo in an experimental mouse model of 
neuropathic pain at CB2.  However, in light of the data gathered at CB1 in our current study, this 
anti-nociceptive activity observed may be mediated through CB1 dependent pathways. 
 
Results from the present study allow C2 to be characterised as an ago-allosteric modulator (ago-
PAM) at CB1, as it has shown to function as an agonist on its own and as an allosteric modulator by 
influencing the efficacy of the endogenous agonist (CP55,940).  However, binding studies are 
needed to confirm whether C2 actually binds to the orthosteric site.  It is also important to note that 
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the presence or absence of ago-PAM activity may depend on the assay system used, giving a 
possible reason as to why it wasn’t detected in Gado et al. (2019) functional studies.  Receptor 
expression and the efficiency of receptor coupling with the activity pathway in question may affect 
how a compound manifests (i.e. a PAM may manifest more like an agonist) (Conn et al., 2014).  
This discrepancy in activity has been demonstrated previously in a series of mGluR5 PAMs 
(Noetzel et al., 2012; Rook et al., 2013).  When there was a high level of mGluR5 expression, many 
of the PAMs showed robust ago-PAM activity; on the contrary, when there were low levels of 
mGluR5 expression, the PAMs behaved as ‘pure’ PAMs, and was unable to exhibit allosteric 
agonist activity.   This is thought to be related to the intrinsic efficacy of the compound, where at 
high receptor expression, even a low efficacy compound may generate a significant effect.  
Additionally, if the signalling pathway in question does not need much priming, it may manifest 
differently.  This reiterates the importance of conducting different assays as it can dictate the in 
vitro profiles of allosteric modulators.  Although the primary focus of this study was investigating 
allosteric modulators at CB2, this significant finding of C2 acting as an ago-PAM at CB1 should be 
further explored.  A potential benefit of ago-PAM activity is that they may provide clinical utility in 
disease conditions where endogenous neurotransmitters are reduced.  Here, the optimisation of an 
ago-PAM is preferable, as the use of a PAM may not be sufficient in such disease conditions (due 
to a lack of endogenous ligand) (Foster & Conn, 2017). 
 
Overall, C2 can be observed to show agonist activity at both CB1 and CB2 (in the absence of EC50 
CP55,940).  C2 belongs to a group of compounds that were obtained by modifying the structure of 
2-oxopyridine-3-carboxamides derivatives of general structures, which have previously been shown 
to be orthosteric cannabinoid receptor ligands (Gado et al., 2019).  This helps explain why C2 
showed activity at both CB1 and CB2.  It may be feasible that some of the original properties were 
retained and that its putative binding site is easily accessible and located in both cannabinoid 
receptors.  
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Results for A5 showed that this compound caused a significant increase in ΔBRET.sec (p<0.05) 
from vehicle, suggesting that this compound may be an inverse agonist at CB1 (Figure 12F). 
However, no significant change was observed for A5 in the presence of EC50 CP55,940.  Hence A5 
displays no allosteric activity at CB1.  If A5 were binding orthosterically and blocking activity, a 
decrease in the CP55,940 signal would be expected when A5 and CP55,940 were combined. 
However, our results show that A5 does not compete with the CP55,940 response, raising the 
possibility that A5 may act non-specifically.  Further studies should aim to test this compound in 
HEK cells without the expression of a receptor, as there is very little evidence that A5 is acting 




Several different analogues (UOSD029, UOSD030, UOSD031) were created based on structure-
activity relationship analysis of C2 and A5.  The scaffolds in the published literature suggested that 
closely related analogues in this compound class could behave as orthosteric and/or allosteric 
ligands.  It was suggested that the way this ligand class binds orthosterically is likely to be with the 
N-benzyl pointing ‘down’ into the CB2 receptor in a hydrophobic environment.  Hence, the 
rationale behind the design of these analogues was to put polar substituents off the N-benzyl to try 
and reduce classical orthosteric binding. 
 
The analogues were tested at the CB2 receptor alone and in the presence of EC50 CP55,940 to 
detect any allosteric properties.  No concentration-dependent responses were observed for 
UOSD029 and UOSD030 alone (Figure 14D and 14E), and this was confirmed by a lack of 
significant difference in the AUC analysis (Figure 15A).  On the contrary, UOSD031 may be a 
weak inverse agonist at CB2 as there was a small but significant increase in ΔBRET.sec at high 
concentrations (Figure 14F and 15A).  In the presence of EC50 CP55,940, UOSD029 significantly 
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increased G protein dissociation, suggesting that this compound may be a PAM at CB2 (Figure 15B), 
Although, upon observation of the concentration response curve (Figure 14J), the magnitude of this 
effect is small.  No significant changes were observed for the remaining analogues (UOSD030 and 
UOSD031) in the presence of EC50 CP55,940, suggesting that they have no allosteric effects.  
However, consistent with the UOSD031 data in the absence of CP55,940, G protein dissociation 
appeared to be slightly decreased at very high concentrations (31.6µM) (Figure 14L).  A possible 
explanation for why the remaining analogues showed no allosteric activity is that the structural features 
that allow orthosteric binding may overlap with the allosteric binding components.  Hence, when the 
polar substituents off the N-benzyl were added to reduce the classical orthosteric binding, the 
allosteric binding properties may have also been affected.  Prior to designing C2 and A5 analogues, 
more compelling evidence needs to be gathered to support whether these compounds bind to 
different sites to CP55,940 (allosteric sites as opposed to the orthosteric site), as there was a lack of 
properly designed binding assays in both Gado papers (as discussed earlier, the binding data is 
complex to interpret, and the data has not been controlled correctly).  Additionally, considering no 
significant changes were observed for C2 and A5 in the presence of EC50 CP55,940 in the G 
protein assay, it is not surprising that little evidence for allosteric activity was observed under the 
same conditions.  Overall, this data suggests weak allosteric inverse agonism, especially regarding 
UOSD031.  Therefore, further studies should be conducted to confirm that the effects seen are 
allosteric, prior to conducting further structure-activity studies to extend the activity of these 
analogues. 
 
4.1.4. Virtual Screen Compounds 
 
An in silico screen of putative allosteric modulators by the Department of Chemistry identified a 
number of possible candidate compounds, two of which were commercially available prior to the 
start of this project; Z274398656 (Z2; Enamine) and Haloperidol. Z2 and Haloperidol were 
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purchased and tested at CB2, both in the presence and absence of EC50 CP55,940.  There appeared 
to be a small effect at high concentrations in the presence of CP55,940 (Figure 10K and 10J), but 
when AUC analysis was performed (Figure 11), this effect was not statistically significant.  Overall, 
significant modulation of CP55,940-mediated G protein dissociation was not observed (Figure 11B) 
(p<0.05) for either compound, indicating that they are not allosteric modulators of CB2. 
The virtual screen conducted suggested an additional collection of putative allosteric modulators 
(IL-45507, IL-45512, IL-45514, IL-405517), which were also investigated in the G protein 
dissociation assay.  Although results from the raw kinetic traces for the IL-4 compounds at CB2 
detected no apparent concentration dependent changes, and no concentration-response was 
observed (Figure 16), statistical testing detected a significant increase in ΔBRET.sec from vehicle 
for all compounds analysed by AUC analysis at 10µM (Figure 17A).  Looking at the AUC analyses, 
the statistically significant differences may not accurately reflect the activity of these drugs’ 
activities as a baseline shift is visible between the vehicle point and the lowest drug concentration in 
the series.  This is surprising as the vehicle was maintained constant through all ligand 
concentrations and in the vehicle conditions.  This may suggest that the vehicle-baseline shift likely 
reflects an assay or technical artefact.  In the presence of the orthosteric ligand, all IL-4 compounds, 
very modestly, decreased G protein dissociation in the presence of CP55,940, and this reached 
statistical significance in the AUC analysis at 10µM drug concentration (p<0.05) (Figure 17B).   
 
In hopes of detecting positive allosteric activity, a differential experimental design was adopted to 
further investigate and clarify the significant results obtained for the IL-4 compounds in the 
presence of EC50 CP55,940.  An analogue of C2 and A5, UOSD029, was also included in this 
variation of the experimental design as this compound was able to significantly increase G protein 
dissociation in the presence of CP55,940 in the original experimental design.  Three concentrations 
of IL-4 compound and UOSD029 (10 nM, 100 nM, and 1 μM) were independently added to 
CP55,940 concentration-response curves and assessed in HEK293 cells transiently expressing CB2.  
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The rationale for implementing this experimental approach was that allosteric modulators have the  
theoretical ability to be silent in the absence of agonist, and their effects vary across the range of 
concentrations at which the agonist is active.  Considering the accruing data suggesting that the 
compounds under investigation may not be active at CB2, it was hoped that this alternative 
approach would provide a more sensitive means of investigating possible subtle allosteric 
compound effects that are agonist-dependent.  However, results showed that there were no 
significant changes in either efficacies (Emax) or potencies (EC50 values) between CP55,940 alone 
or in combinations with any concentrations of the IL-4 compounds and UOSD029 (Figure 18) 
(Table 1) (p < 0.05).  This confirms that the very small effects observed in the previous experiment 
are unlikely to be biologically relevant, suggesting that these compounds do not possess allosteric 
activity.  Therefore, any significance detected previously with these compounds is more likely to be 
attributable to an assay artefact, or in the case of USD029, high variability between biological 
replicates.  
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4.2. β-arrestin-2 Translocation 
 
G protein-coupled receptors can signal through pathways other than traditional G protein-mediated 
pathways.  Arrestins are molecules that uncouple from receptors from their respective G proteins 
and are known to be implicated in receptor internalisation and desensitisation (Luttrell & 
Lefkowitz, 2002).  As mentioned earlier (Chapter 1), allosteric modulators can show biased 
signalling.  Hence, biased PAMs or NAMs might provide significant clinical value if they can 
potentiate or inhibit the response of the orthosteric agonist for one signalling pathway versus 
another (e.g. G proteins over β-arrestins).  Therefore, it was essential that the in-depth 
characterisation of these novel and proposed allosteric modulators be extended to include more than 
one assay system to investigate a wider range of receptor responses.  In particular, β-arrestin-2 
translocation was of interest at the CB2 receptor. 
 
4.2.1. Published Compounds at CB2: C2 and A5 
 
β-arrestin-2 translocation was investigated for C2 and A5, at the CB2 receptor alone and in the 
presence of EC50 CP55,940.  Results showed that C2 alone significantly increased β-arrestin 
translocation above vehicle levels (p<0.05), indicating that this compound may be an agonist at 
CB2 (Figure 22A).  Similar to the G protein dissociation assay, C2 could not modulate EC50 
CP55,940-dependent β-arrestin-2 recruitment activity (Figure 22B).  A5 alone also showed a very 
small but significant decrease (p<0.05) in β-arrestin translocation from vehicle, indicating that this 
compound may be a weak inverse agonist (Figure 22A).  This is contrary to the results obtained from 
the G protein dissociation assay, where A5 was inactive at CB2.  Although the statistical testing was 
significant, this may not be biologically relevant as the size of the effect was so small.  Similar to 
the G protein dissociation assay, A5 did not significantly modulate EC50 CP55,940-dependent β-
arrestin-2 recruitment activity (Figure 22B).  This directly contradicts the published literature 
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findings that show C2  and A5 to be PAMs of CP55,940-dependent β-arrestin-2 recruitment at CB2.  
Gado et al. (2021) showed that both compounds enhanced β-arrestin-2 recruitment in the presence 
of 10 nM CP55,940 above the effect produced by 10 nM CP55,940 alone, with the enhancement of 
the CP55,940-dependent effect by A5 being of lower potency than that of C2.  A possible 
explanation for the differences seen between the current project and published literature may be 
attributed to the differences in methodologies used.  The published literature used a different β-
arrestin-2 translocation assay to the current project, a CB2 CHO–K1 cell PathHunter assay 
(DiscoveRx®).  The PathHunter β- arrestin assay principle involved the ProLink (PK) tagged CB2 
receptor, and the Enzyme Acceptor (EA) tagged β-arrestin.  Upon activation of the CB2 receptor-PK 
complex,  β-arrestin-EA recruitment to the complex occurs, consequently leading to the 
complementation of the two β-galactosidase enzyme fragments (EA and PK) hydrolysing the 
Galacton Star substrate to create a chemiluminescent signal (Wang et al., 2017).  Additionally, the 
affinity between the β-galactosidase enzyme fragments may enhance the stability of the receptor-
arrestin complex in a non-specific manner.  Whether this affects the ability of receptors in the 
PathHunter assay to recruit β-arrestin is yet to be clarified.  Ultimately, this would make it difficult 
to characterise pharmacological properties (efficacy, potency, and kinetics) (Donthamsetti et al., 
2015).  Another important consideration that needs to be mentioned is that in the published 
literature, cells were co-treated with the CB2 ligands for 90 minutes, with an additional 60 minute 
incubation period in detection solution, contrary to the β-arrestin-2 translocation assay used in the 
current project, where data was only collected for 25 minutes following drug addition (in real-time).  
This difference in time may be a variable that could have led to the differences in results observed.  
CB2 internalises rapidly in response to an agonist (Grimsey et al., 2011); therefore, the effect Gado 
et al. (2021) have observed may be occurring intracellularly following internalisation of the 
receptor, as opposed to the results seen in this current study. 
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The commercially available compounds Z2 and Haloperidol were also tested in this assay 
paradigm, but neither compound showed a statistically significant difference from vehicle at CB2 
and did not modulate EC50 CP55,940-dependent β-arrestin-2 recruitment activity (Figure 22).  This 
aligns with previous observations and results from the G protein dissociation assay, indicating that 
neither of these compounds is active at CB2, and no allosteric behaviour was present. 
 
4.2.2. Virtual Screen Compounds 
 
IL-4 compounds from the virtual screen were tested in the β-arrestin-2 translocation assay at a 
single concentration (31.6µM) in the absence or presence of EC50 CP55,940 at CB2 (Figure 23). 
There were no statistically significant changes to be reported either at the receptor alone or in the 
presence of EC50 CP55,940 at CB2 (Figure 24).  However, only two biological replicates were 
included in the statistical testing, and an assay artefact was present in one replicate, limiting the 
conclusions that could be drawn from these data.  Further replicates would allow for greater 
statistical power and better conclusions to be made.  In addition, the study of these IL-4 compounds 
should be extended to investigate full concentration-response curves for all compounds in the 
absence and presence of EC50 CP55,940, allowing more robust conclusions to be made.  This 
would allow the comparison of the potencies and efficacies of each compound.  Lastly, an 
important consideration of this data set is that higher concentrations could exceed the solubility 
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4.3. Limitations and Future Studies 
 
 
Further replicates are needed for these compounds, as additional replicates may allow for greater 
statistical power and more statistically significant conclusions to be drawn.  However, identifying 
statistical significance should not be the primary objective of statistical analysis.  Even if a  
significant effect is observed, it may be biologically irrelevant (statistical significance is smaller 
than the biologically relevant effect size) (Committee, 2011).  As seen throughout this study, the IL-
4 compounds from the in silico virtual screen and UOSD029 (analogue of C2 and A5) could not 
consistently modulate CP55,940-dependent G protein dissociation.  Although the effect seen in the 
original experimental design (increasing allosteric modulator concentrations in the presence of 
EC50 CP55,940) was statistically significant, the magnitude of the effect was likely too small to be 
biologically important.  This was further elucidated in the other experimental design where neither 
the IL-4 compounds or UOSD029 could significantly modulate the CP55,940 concentration-
response curves at any of the concentrations of compound used (10 nM, 100 nM, and 1 μM) (Figure 
17, Table 1).  The statistical significance obtained from some experimental approaches is therefore 
likely artefactual, and may be explained by attributes such as off-target effects at high allosteric 
modulator concentrations, or a technical issue (such as a plate layout effect). 
 
Limitations are also present for the BRET assay used.  While it has advantages in maintaining 
native receptor structure, this assay has a lower dynamic range in relation to other BRET-based 
arrestin assays such as the PathHunter Assay (Donthamsetti et al., 2015).  In addition to this, assays 
like the PathHunter assay measure interactions between receptors and arrestin, contrary to the 
arrestin translocation assay used in this project, which measures arrestin recruitment to the 
membrane.  Nevertheless, the β-arrestin translocation assay is preferred over the PathHunter β-
arrestin assay as it allows the use of a wildtype (wt.) receptor as opposed to a tagged receptor.  
Hence,  the assay is not affected by conditions that may alter normal signalling or artificially 
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modulate the pharmacological activity (as mentioned previously).  Since the current study did not 
include “no receptor” controls, future studies could utilise the use of a wildtype (wt.) receptor to 
investigate whether the effects seen are receptor-mediated, especially for C2.  
 
Further studies on these novel, putative allosteric modulators should extend to include radioligand 
binding studies as they provide critical information in structure-activity relationships.  The 
published literature conducted CP55,940 binding assays on C2 and A5; however, the current project 
did not carry out any binding assays due to time constraints.  Results from the published literature 
showed that C2 increased the binding of [3H]CP55,940 at both CB1 and CB2.  The evidence 
obtained at CB1 correlates with what was observed in the G protein dissociation assay conducted at 
CB1 in the present project, as results were consistent with ago-PAM activity.  However, the current 
project could not detect any PAM activity at CB2 in either the G protein dissociation assay or the β-
arrestin translocation assay.   Therefore, it is essential that these binding assays are repeated; as 
observed throughout this project, much of the data from the published literature could not be 
reproduced.  In addition, conducting binding assays on the remaining novel allosteric compounds in 
this current study (virtual screen compounds and analogues) would have been helpful in the 
characterisation process.   
 
Further studies should also aim to replicate the [35S]GTPγS binding assays at both CB1 and CB2, as 
it would be interesting to see whether this data can be reproduced or whether it may be 
contradicting.  The GTPγS assay conducted in the Gado papers and the G protein dissociation 
conducted in this current study measure similar endpoints (G protein activation).  However, 
differences exist between the assays; notably, G protein dissociation is assayed in live cells, 
whereas GTPγS assay is performed using cell membranes (a more reductionist method, where 
receptor internalisation does not occur).  This could contribute to the differences observed between 
the two studies.  Additional studies should also aim to investigate C2 at CB1 in the β-arrestin 
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translocation assay, as there was clear evidence for this compound to act as an ago-PAM in the G 
protein Dissociation assays.  This may allow the determination of whether C2 may show biased 
signalling at CB1. 
 
As mentioned (Chapter One), allosteric modulators may also show probe dependence (Bartuzi et 
al., 2019).  When a different orthosteric ligand binds to the endogenous site, it may induce different 
receptor conformations, affecting the ability of an allosteric ligand to modulate that agonist.  
Therefore, allosteric modulators may produce different levels of modulation depending on what 
orthosteric agonist is present.  Probe dependence may result in a loss of selectivity of an allosteric 
ligand for a specific receptor or a complete alteration in the mode of action (Klein et al., 2013).  
This can have major implications for the functional characterisation of allosteric modulators and 
extending the structure-activity relationships (SARs) for these novel modulators.  For example, in 
the GTPγS assays conducted by Gado et al. (2019), results showed C2 (100 nM) to enhance the 
ability of CP55,940 and 2-AG but not AEA to stimulate G protein activation. 2-AG and AEA hold 
immense significance, considering that they are the primary endocannabinoids.  Overall, as research 
into these novel compounds progresses, alternative agonists should be considered when more 
deeply characterising the allosteric effect. 
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5.  Conclusion  
There is an emerging interest in designing and developing allosteric compounds at CB2. 
C2 and A5 are novel synthetic compounds that have been previously characterised as positive 
allosteric modulators of CB2.  However, results from this present study does not align with previous 
studies, which has characterised C2 and A5 as PAMs; here, neither compound was able to modulate 
CP55,940-dependent G protein dissociation or CP55,940-dependent β-arrestin-2 translocation at 
CB2.  However, C2 showed intrinsic activity in the absence of an orthosteric ligand, suggesting that 
this compound may be an “allosteric agonist” or an “agonist” at CB2.  Binding studies are necessary 
to elucidate this characterisation of C2 further.  Surprisingly, C2 showed ago-PAM activity at CB1. 
This is an important avenue that may be worth exploring, as compounds showing ago-PAM activity 
hold clinical significance over PAMS in disease conditions where endogenous neurotransmitters are 
reduced.  Further studies for C2 at CB1 could be extended via characterising β-arrestin-2 
translocation effects.   
 
The remaining set of novel allosteric compounds (C2 and A5 analogues, and “hits” from the in 
silico virtual screen) did not show any evidence of allosteric activity at CB2.  Nevertheless, the 
findings from this study elucidate dissimilarities from published literature, which present C2 and 
A5 as PAMs.  Our findings clarify that C2 was not able to attain the theoretical advantages of 
allosteric modulators, as C2 could not show selectivity for CB2 and had intrinsic activity in the 
absence of an orthosteric ligand.  As mentioned before, some results do require further replications 
to come to more robust conclusions.  Conducting SAR studies may also benefit the subsequent 
development of the reported CB2 PAMs to improve potency, selectivity, and pharmacokinetics.  
This may allow a clearer understanding of the biochemical and behavioural properties of these first‐
generation CB2 allosteric modulators.  Further studies should address the issues that arise with 
different receptor expression levels, issues associated with biased signalling, and the 
characterisation of ago-PAM versus pure PAM activities.  Despite these challenges, the advantages 
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of allosteric modulation of CB2 provide exciting new opportunities to discover novel agents, as it 
provides a new way to target the endocannabinoid system.   
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7. Appendix 
Materials and Reagents 
 
 
Item Source Catalogue No. 
Bovine Serum Albumin 
(BSA), Fatty acid-free  
MP Biomedicals New Zealand, Auckland ABFF-100G  
Coelenterazine-h  Nanolight Technology, Prolume Ltd., 
Pinetop, AZ  
301-1  
Coelenterazine-400a Nanolight Technology, Prolume Ltd., 
Pinetop, AZ 
340-1 
Corning® 75 and 25 cm2 
rectangular canted neck 
cell culture flasks with 
vent caps  
 







microplate, sterile and 
tissue culture treated  
 




CP55,940 Cayman Chemical Co, Ann Arbour, MI 90084 
Dimethyl sulphoxide 
(DMSO) certified AR  
Sigma Aldrich, St. Louis, MO  276855-1L 
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Dulbecco’s Modified 
Eagle’s Medium 
(DMEM), phenol red  





(DMEM), no phenol red  




Ethanol Absolute AR 
20L ACS Grade 
Lab Supply, Dunedin  CHELETHD1E2292.1 
Foetal bovine serum 
(FBS), NZ-origin  
Moregate Biotech  FBSF 
Haloperidol Cayman Chemical Co, Ann Arbour, MI 12014 
Opti-MEMTM reduced 
serum medium 
Thermo Fisher Scientific, Waltham, MA  
 
31985-062  
Poly-D-Lysine (PDL) Sigma Aldrich, St. Louis, MO  P1149 
Polyethyleneimine 25K 
(PEI-MAX)  
Polysciences, Warrington, PA  24765-1  
Trypan blue solution, 
0.4%  
Thermo Fisher Scientific, Waltham, MA  15250061  
Trypsin/EDTA (0.05%, 
1x), phenol red  
Thermo Fisher Scientific, Waltham, MA  25300054  
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ZeocinTM selection 
reagent 
Thermo Fisher Scientific, Waltham, MA  
 
R250-01  
LUMIStar  BMG Labtech GmbH, Ortenberg Germany  N / A 
 
